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Abstract
Introduction Anemia is one of the most common medical
complications to be encountered in critically ill patients. Based
on the results of clinical trials, transfusion practices across the
world have generally become more restrictive. However,
because reduced oxygen delivery contributes to 'secondary'
cerebral injury, anemia may not be as well tolerated among
neurocritical care patients.
Methods The first portion of this paper is a narrative review of
the physiologic implications of anemia, hemodilution, and
transfusion in the setting of brain-injury and stroke. The second
portion is a systematic review to identify studies assessing the
association between anemia or the use of red blood cell
transfusions and relevant clinical outcomes in various
neurocritical care populations.
Results There have been no randomized controlled trials that
have adequately assessed optimal transfusion thresholds
specifically among brain-injured patients. The importance of
ischemia and the implications of anemia are not necessarily the
same for all neurocritical care conditions. Nevertheless, there
exists an extensive body of experimental work, as well as human
observational and physiologic studies, which have advanced
knowledge in this area and provide some guidance to clinicians.
Lower hemoglobin concentrations are consistently associated
with worse physiologic parameters and clinical outcomes;
however, this relationship may not be altered by more
aggressive use of red blood cell transfusions.
Conclusions Although hemoglobin concentrations as low as 7
g/dl are well tolerated in most critical care patients, such a
severe degree of anemia could be harmful in brain-injured
patients. Randomized controlled trials of different transfusion
thresholds, specifically in neurocritical care settings, are
required. The impact of the duration of blood storage on the
neurologic implications of transfusion also requires further
investigation.
Introduction
A key paradigm in the management of neurocritical care
patients is the avoidance of 'secondary' cerebral insults [1-3].
The acutely injured brain is vulnerable to systemic derange-
ments, such as hypotension, hypoxemia, or fever, which may
further exacerbate neuronal damage [4-7]. Thus, critical care
practitioners attempt to maintain a physiologic milieu that min-
imizes secondary injury, thereby maximizing the chance of a
favorable functional and neurocognitive recovery.
Anemia is defined by the World Health Organization as a
hemoglobin (Hb) concentration less than 12 g/dl in women
and 13 g/dl in men [8]. It is one of the most common medical
complications encountered in critically ill patients, including
those with neurologic disorders. About two-thirds of patients
have Hb concentrations less than 12 g/dl at the time of inten-
sive care unit (ICU) admission, with a subsequent decrement
of about 0.5 g/dl per day [9-12]. The etiology of ICU-acquired
anemia is multifactorial. Systemic inflammation reduces red
CBF: cerebral blood flow; CaO2: arterial oxygen content; CMRO2: cerebral metabolic rate; CO: cardiac output; CO2: carbon dioxide; CPP: cerebral 
perfusion pressure; DO2: oxygen delivery; Hb: hemoglobin; HBBS: hemoglobin-based blood substitutes; ICH: intracerebral hemorrhage; ICU: inten-
sive care unit; LPR: lactate to pyruvate ratio; MRI: magnetic resonance imaging; NO: nitric oxide; O2: oxygen; OEF: oxygen extraction fraction; PbtO2: 
brain tissue oxygen tension; PCO2: partial pressure of carbon dioxide; PET: positron emission tomography; PO2: partial pressure of oxygen; RBC: 
red blood cell; RCT: randomized controlled trial; SAH: subarachnoid hemorrhage; SaO2: oxygen saturation; SjvO2: jugular venous oxygen saturation; 
TBI: traumatic brain injury.Critical Care    Vol 13 No 3    Kramer and Zygun 
Page 2 of 22
(page number not for citation purposes)
blood cell (RBC) development by blunting the production of
erythropoietin and interfering with the ability of erythroblasts to
incorporate iron [13-17]. RBC loss is accelerated by frequent
phlebotomy, reduced RBC survival, and occasional hemor-
rhage. Large volumes of fluid used during resuscitation, with
resultant hemodilution, may also contribute to early reductions
in Hb levels [18-22].
Anemia can easily be corrected with the use of allogeneic
RBC transfusions. The proportion of patients receiving blood
during their ICU stay varies from 20 to 44%, and those who
are transfused receive an average of as many as five units
[10,11,23,24]. However, two multi-center, randomized con-
trolled trials (RCTs) and two large observational studies have
shown the liberal use of blood transfusions, with the goal of
maintaining relatively arbitrary Hb concentrations (e.g. 10 g/
dl), to not only be ineffective at improving outcomes, but also
potentially harmful [10,11,25,26]. Still, because impaired oxy-
gen (O2) delivery is thought to be an important factor in sec-
ondary brain injury, it remains uncertain whether these findings
can be broadly applied to neurocritical care patients. Accord-
ingly, it remains common practice for clinicians to set target
Hb levels at a minimum of 9 to 10 g/dl in this setting [27-29].
Materials and methods
To describe the physiologic and clinical implications of anemia
and transfusion in neurocritical care patients, we used the
OVID interface to search MEDLINE from its inception until
March 9, 2009. We combined the following MESH headings:
(anemia OR blood transfusion OR hemodilution OR hemat-
ocrit OR hemoglobins) AND (stroke OR craniocerebral trauma
OR subarachnoid hemorrhage OR cerebral hemorrhage OR
cerebrovascular circulation OR cardiac surgical procedures
OR coronary artery bypass). This search yielded 2137 English
language publications dealing primarily with adults (>18 years
old). Each abstract was reviewed, and both human and animal
studies assessing the impact of anemia, hemodilution, or the
use of RBC transfusions on a physiologic or clinical outcome
were chosen for more detailed review. Relevant review articles
and case reports were also included, and the references of
selected papers were screened for additional publications.
Clinical studies involving specific groups of neurocritical care
patients were selected for inclusion in evidentiary tables.
Results and discussion
Physiologic implications of anemia
Cerebral blood flow and oxygen delivery
The amount of oxygen reaching specific organs is the product
of local blood flow and the arterial oxygen content (CaO2). The
latter is dependent on the Hb concentration and the degree to
which it is saturated with O2 (SaO2), with a small amount of O2
also dissolved in blood. Thus, global systemic O2 delivery can
be expressed by the following equation:
O2 delivery to the brain can be conceptualized using the same
equation, but by substituting cerebral blood flow (CBF) for
cardiac output (CO). Flow through the cerebral vasculature is
determined by the cerebral perfusion pressure (CPP), the
length and caliber of the vessels, and the viscosity of blood, as
described by the Hagen-Poiseuille equation:
Regulation of CBF and cerebral O2 delivery in response to
physiologic stressors is achieved largely by homeostatic varia-
tions in the caliber of cerebral vessels (the 'r' in the above
equation; Figure 1).
CPP is the difference between mean arterial pressure and cer-
ebral venous pressure; intracranial pressure is widely used as
a surrogate for the latter. The response of the cerebral vascu-
lature to changes in CPP is referred to as CBF autoregulation
('pressure-reactivity'). Cerebral arterioles vasoconstrict in
response to raised CPP and vasodilate when there are reduc-
tions, thereby maintaining constant CBF (Figure 1a). Autoreg-
ulation is sometimes impaired in neurocritical care patients,
such that CBF becomes directly dependent on CPP, making
the brain more vulnerable to both hypo- and hyperperfusion
[30-32].
There are numerous other stimuli that may modify cerebral vas-
cular resistance and CBF. Both global and regional CBF are
tightly coupled to metabolism. Thus, physiologic changes that
lead to a reduction in cerebral metabolic rate (CMRO2) (e.g.
hypothermia or sedation) will also proportionally reduce CBF
(Figure 1b). In addition, CBF is influenced by variations in the
partial pressures of carbon dioxide (PCO2; 'CO2-reactivity'),
and to a lesser degree, O2  (PO2) (Figures 1c, d). CBF
increases in response to a decrease in PO2, although this
effect is probably minimal until the level approaches 60 mmHg
[30].
In response to worsening anemia, neuronal O2 delivery is ini-
tially preserved both by the systemic cardiovascular response
and mechanisms that are more specifically neuroprotective.
Cardiovascular response to anemia
A falling Hb concentration is sensed by aortic and carotid
chemoreceptors, resulting in stimulation of the sympathetic
nervous system, which in turn raises heart rate and contractil-
ity, thereby augmenting CO [33-35]. The reduction in blood
viscosity results in a corresponding reduction in afterload, as
well as enhanced flow through post-capillary venules, greater
venous return, and increased preload [36-38]. Thus, stroke
volume, CO, and blood pressure (as well as CPP) increase in
response to isovolemic anemia. Tissues are further protected
from falling O2 delivery because of their capacity to increase
O2 extraction and maintain constant O2 consumption. In the
brain, irreversible ischemia may not occur until the O2 extrac- DO ml O min cardiac output L min Hb g L S O a 22 213 (/ ) ( / ) ( ( / ) ( ( % ) . =× × × 9 9 0 003 22 ( / )) ( . )) ml O g Hb PO +×
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tion fraction (OEF) exceeds 75% [39-43]. Systemic anaerobic
metabolism does not develop until the Hb concentration falls
well below 5 g/dl in otherwise healthy individuals [44]. On the
other hand, many neurocritical care patients have concomitant
cardiac disease and left ventricular dysfunction which may
prevent an appropriate increase in CO in response to sympa-
thetic stimulation. This is commonly the case even in the
absence of pre-existing heart disease; for example, among
patients with acute 'high-grade' aneurysmal subarachnoid
hemorrhage (SAH) (Hunt-Hess grades 3 to 5), more than one-
third have regional left ventricular wall motion abnormalities
detectable by echocardiography [45].
Cerebrovascular response to anemia
Apart from the increased flow produced by higher CPP and
lower blood viscosity, anemia also induces cerebral vasodila-
tation [46-48]. When Hb (and therefore CaO2) falls, there
appears to be a disproportionate increase in CBF in relation to
other organs (Figure 1d) [49]. The mechanisms underlying this
increase in vessel caliber are still being clarified, but include
some of the same factors involved in CBF pressure-autoregu-
lation; these have recently been reviewed in detail [46]. Impor-
tantly, anemia results in upregulation of nitric oxide (NO)
production by perivascular neurons and vascular smooth mus-
cle surrounding cerebral blood vessels. The importance of
these pathways is supported by the observation that inhibition
of NO synthase blunts hypoxia- and anemia-induced cerebral
vasodilatation [50-52]. However, additional factors are
undoubtedly involved [53-55]. Sympathetic β2 receptor stim-
ulation is an example of one such mechanism that contributes
to vasodilatation and maintenance of CBF [56]. Other bio-
chemical mediators that are upregulated in the brain in
response to anemia include vascular endothelial growth factor,
hypoxia inducible factor 1α, and erythropoietin [46,57].
Although it seems likely that these mediators are neuroprotec-
tive, it remains possible that they could also have harmful
pathophysiologic effects [46].
Compensatory mechanisms eventually fail
As anemia worsens, the resultant increases in CBF and OEF
eventually become insufficient to overcome the reduced CaO2
produced by a low Hb concentration (Figure 2). The point at
which this threshold is reached is not clear and probably varies
somewhat between patients. A sophisticated mathematical
model based on animal data suggested that CMRO2 is well
preserved in normal brain, even with severe reductions in Hb
concentration. In contrast, penumbral brain appears to be
much more vulnerable, with O2 delivery and CMRO2 progres-
sively declining as Hb falls below 10 to 12 g/dl [58-62]. As
with cerebral ischemia, impairment of the usual protective
mechanisms induced by anemia has also been demonstrated
as a result of brain trauma [63].
Figure 1
Physiologic parameters influencing cerebral blood flow Physiologic parameters influencing cerebral blood flow (a) The effects of mean arterial blood pressure (MAP) (solid line = normal autoregulation; 
dashed line = deranged autoregulation), (b) cerebral metabolic rate (CMRO2), (c) partial pressure of carbon dioxide (PCO2), (d) partial pressure of 
oxygen (PO2) and arterial oxygen content (CaO2) (solid curved line = PO2; dashed line = CaO2) are shown. CBF = cerebral blood flow.Critical Care    Vol 13 No 3    Kramer and Zygun 
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A study of euvolemic hemodilution in healthy human volunteers
confirmed that even profound anemia (Hb about 5 g/dl) was
relatively well tolerated; however, subtle abnormalities in neu-
rocognitive testing began to emerge when Hb concentrations
fell below 7 g/dl [64,65]. The co-existence of other physiologic
stressors may also make anemia less tolerable; for example,
experimental studies have found that cerebral O2 delivery is
preserved in the presence of both severe anemia and hypoten-
sion individually, but not when they are both present [66,67].
Additionally, anemia-induced cerebral vasodilatation appears
to interfere with the usual response to variations in PCO2
[47,68-70]. These observations raise concerns that relatively
inadequate O2 delivery could occur at Hb levels well above 7
g/dl in critical care patients with cerebrovascular disease, pre-
existing central nervous system pathology (e.g. an ischemic or
'traumatic' penumbra) or deranged regulation of CBF. Thus,
there is strong physiologic rationale for believing that a restric-
tive transfusion threshold of 7 g/dl, although clearly safe in
many critical care patients [25,26], may not be without risk in
neurocritical care patients.
Risks of red blood cell transfusion
Even if anemia is harmful, this does not necessarily prove that
liberal use of allogeneic RBCs to normalize Hb concentrations
is justified. Emerging data indicates that stored blood has
important differences from patients' own blood. A number of
changes occur over time as RBCs are being stored; some of
these alterations could have important implications after trans-
fusion, and they are collectively referred to as the 'storage
lesion'. Biochemical changes include reductions in ATP, loss
of membrane phospholipids, and oxidative damage to pro-
teins. The consequence is a gradual change in RBC appear-
ance from the usual biconcave discs to irreversibly deformed
and stellate-shaped spheroechinocytes [71,72]. Loss of RBC
membrane function, as well as an increased tendency to
adhere to endothelium, may interfere with microcirculatory
flow [72,73]. RBC 2-3-diphosphoglycerate levels become
depleted to the point of being essentially undetectable after
one week of storage. Although levels are usually restored
within 24 to 72 hours after transfusion, the transiently
increased binding affinity of Hb interferes with the release of
O2 for use by tissues [74].
Thus, although blood transfusions are generally given with the
intention of raising O2 delivery, the storage-induced changes
may prevent RBCs from achieving their intended purpose. For
example, studies using gastric tonometry parameters as a sur-
rogate for mesenteric perfusion have not shown improvements
following transfusion [75,76]. Similarly, RBCs also appear to
have little effect on skeletal muscle O2 tension in postoperative
patients or on global O2  consumption in the critically ill
[77,78].
Transfusion-related acute lung injury is now the most common
cause of transfusion-related mortality reported to the Food and
Drugs Administration [79]. Transfusion may have immunosup-
pressive effects, which are thought to be due to concomitant
white blood cell transmission. Several studies have suggested
a link between the use of allogeneic RBCs and both nosoco-
mial infections and acute respiratory distress syndrome [80-
83]. Alternatively, RCTs, where well-matched groups were
transfused with differing intensities, have not yet convincingly
confirmed these associations [25,26]. Furthermore, the risk of
Figure 2
Effects of falling hemoglobin concentration on cerebral oxygen delivery Effects of falling hemoglobin concentration on cerebral oxygen delivery. With mild hemodilution, it is theoretically possible that the resultant increase 
in cerebral blood flow (CBF) can raise overall O2 delivery. However, with further decrements in hemoglobin, the increment in CBF is insufficient to 
overcome the reduction in arterial oxygen content (CaO2).Available online http://ccforum.com/content/13/3/R89
Page 5 of 22
(page number not for citation purposes)
complications may be less since the implementation of univer-
sal leukoreduction in many jurisdictions [84].
It has been suggested that the use of fresher blood might fur-
ther minimize the risks of transfusion, while also maximizing
their physiologic effect. Results have been conflicting, and
there is little data specifically in neurocritical care patients
[71,75,76]. A recent animal study found fresh blood to be
more effective at raising brain tissue oxygen tension (PbtO2)
and preserving CBF in comparison to stored blood [85]. Alter-
natively, Weiskopf and colleagues performed isovolemic
hemodilution to Hb concentrations of 55 to 74 g/L in healthy
volunteers and then transfused them with autologous blood
stored for either less than five hours or more than 14 days;
neurocognitive test performance did not differ between the
two groups [86].
Anemia and RBC transfusion in specific neurocritical 
care settings
The importance of ischemia in causing secondary brain injury
appears to vary for different neurocritical care conditions. For
example, cerebral vasospasm and delayed infarction are major
causes of neurologic deterioration in the two weeks following
a ruptured cerebral aneurysm [87,88]. In contrast, the fre-
quency and relevance of cerebral ischemia in the pathophysi-
ology of traumatic brain injury (TBI) or intracerebral
hemorrhage (ICH) continue to be debated [40,89-91].
Accordingly, the significance of anemia and optimal transfu-
sion thresholds may not be consistent from one condition to
the next.
Lessons from cardiac surgery
A great deal of what is known about the neurologic effects of
anemia has been reported in the cardiac surgical literature. A
substantial proportion of patients undergoing cardiac surgery
receive blood transfusions, even though large volume hemor-
rhage is comparatively less common [92]. Perioperative stroke
occurs in 1 to 6% of patients and is strongly associated with
greater morbidity and mortality [93,94]. An even larger propor-
tion (≥50%) develops at least transient neurocognitive dys-
function that is likely to be, at least in part, due to cerebral
ischemia [95,96]. Thus, the prevention and treatment of cere-
bral ischemia is of major concern in the perioperative period.
We identified 12 studies assessing the association between
perioperative Hb concentrations and subsequent neurologic
complications (Table 1). When defined as an Hb concentra-
tion less than 12.5 g/dl, about one-quarter of patients are ane-
mic preoperatively [97]. Blood loss and hemodilution during
cardiopulmonary bypass usually lead to nadir intraoperative
Hb concentrations of 7.0 to 8.5 g/dl; levels at ICU admission
are typically 8.5 to 9.5 g/dl [98]. Several, but not all, studies
have suggested that the degree of Hb reduction is an inde-
pendent predictor of stroke, delirium, neurocognitive dysfunc-
tion, and other adverse outcomes [97-108] (Table 1).
Although it has not been proven with certainty that these rela-
tions are causative, it seems prudent to avoid major reductions
in Hb as best as possible with relevant blood-conservation
strategies [109-113].
A recent RCT involving 121 elderly patients undergoing coro-
nary artery bypass compared two intraoperative hematocrit
targets (15 to 18% vs. ≥ 27%) [102]. The study was termi-
nated early because of high complication rates in both groups;
however, a greater degree of postoperative neurocognitive
dysfunction was observed among patients managed with
more extreme hemodilution. In addition, although not neces-
sarily directly applicable to adults, further evidence that exces-
sive hemodilution may have harmful neurologic effects comes
from the neonatal literature. Combined data from two RCTs
suggested that hematocrit levels below 23.5% during cardi-
opulmonary bypass were associated with impaired psychomo-
tor development at one year of age [114-116].
Whether using RBC transfusions to maintain higher perioper-
ative Hb levels helps avoid neurologic complications remains
uncertain. For example, although Karkouti and colleagues
found nadir hematocrit levels during cardiopulmonary bypass
to be a predictor of stroke in a multivariable analysis, the same
was also true for the perioperative use of transfusions [105].
An association between transfusion and focal or global neuro-
logic deficits has been confirmed in numerous other studies
(Table 2) [117-125].
One study compared clinical outcomes, including the risk of
perioperative stroke, between 49 Jehovah's Witnesses who
underwent cardiac surgery without blood products and a
matched control group of 196 patients, in whom RBC transfu-
sions were used. No significant differences were observed;
however, only nine patients in total experienced a stroke, such
that this study lacked statistical power to detect a difference.
The severity of anemia in Jehovah's Witness patients was not
reported [123].
In a large, single-center, retrospective study, Koch and col-
leagues explored whether the association between RBCs and
worse outcomes could be related to the duration of blood stor-
age. Outcomes were compared among cardiac surgical
patients depending on whether they were transfused with
exclusively 'newer' (≤14 days old; median 11 days) or 'older'
(>14 days old; median 20 days) blood during the periopera-
tive period [126]. In-hospital mortality and postoperative com-
plications, including sepsis, renal failure, and need for
mechanical ventilation, were greater among patients receiving
older blood. However, there was no significant difference in
the incidence of stroke and coma.
In summary, there remains uncertainty concerning optimum
Hb levels for neuroprotection of patients undergoing cardiac
surgery. Many intensivists routinely employ a postoperativeCritical Care    Vol 13 No 3    Kramer and Zygun 
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Table 1
Adult studies assessing the association between anemia and the development of perioperative stroke or cognitive dysfunction 
among patients undergoing cardiac surgery
Study Patients Design and 
setting
Multivariable 
analysis
Exposure Outcome Main result
Karkouti and 
colleagues [97]
10,179 Retrospective(pro
spective 
database)
Single-center
Logistic 
regression
Maximum 
decrease 
intraoperative Hb 
compared with 
baseline
Composite of in-
hospital death, 
stroke (new 
persistent 
postoperative 
neurologic deficit), 
or dialysis-
dependent renal 
failure
>50% decrement 
in Hb 
independently 
associated with 
composite 
outcome
Bell and 
colleagues [98]
36,658 (CABG) Retrospective 
(prospective 
database)
Multi-center
Logistic 
regression
Preoperative Hb Postoperative 
stroke 
(not further 
defined)
No significant 
association 
between Hb and 
stroke
Karkouti and 
colleagues [99]
3286
(CABG)
Retrospective
Multi-center
Logistic 
regression and 
propensity scores
Preoperative 
anemia 
(Hb <12.5 g/dl)
Postoperative 
stroke 
(new neurologic 
deficit)
- Risk of stroke 
1.1% in non-
anemic pts vs. 
2.8% in anemic 
patients
- Trend towards 
more stroke 
among anemic 
patients in 
propensity-
matched analysis
Chang and 
colleagues [100]
288 Retrospective
Single-center
Logistic 
regression
Postoperative Hct 
<30%
Delirium (DSM-IV 
criteria)
Postoperative hct 
<30% associated 
with development 
of delirium (OR = 
2.2, P = 0.02)
Kulier and 
colleagues [101]
4804 Retrospective 
(prospective 
database)
Multi-center
Logistic 
regression
Preoperative Hb 'Cerebral 
outcomes' = 
stroke or 
encephalopathy 
(not further 
defined)
- Each 10 g/L Hb 
reduction 
associated with 
15% increase in 
risk of non-cardiac 
(renal or CNS) 
complications
- Association 
stronger for renal 
complications
Matthew and 
colleagues [102]
121 
(CABG; age >65)
Prospective RCT
Single-center
Logistic 
regression
Comparison of 
hemodilution to 
hct of ≥27% vs. 
15 to 18%
Six-week 
postoperative 
neurocognitive 
function 
(battery of 5 tests)
- Trial stopped 
early because of 
unusually high rate 
of complications in 
both groups
- Significant 
interaction 
between age and 
hct; more 
neurocognitive 
deficits among 
older patients with 
low hct
Cladellas and 
colleagues [103]
201 (VR) Retrospective 
(prospective 
database)
Single-center
None Preoperative 
anemia 
(Hb <12 g/dl)
New permanent 
stroke or transient 
ischemic attack 
(not further 
defined)
- Risk of TIA or 
stroke 9.5% in 
anemic patients 
vs. 4.4% in non-
anemic
Giltay and 
colleagues [104]
8139 (CABG) Retrospective
Single-center
Logistic 
regression
Lowest hematocrit 
first 24 hours ICU
Psychotic 
symptoms 
(hallucinations 
and/or delusions)
Hct <25% 
associated with 
psychosis (OR = 
2.5 vs. hct >30%, 
CI 1.2 to 5.3)Available online http://ccforum.com/content/13/3/R89
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transfusion threshold of 7 g/dl, although this may not be the
optimum Hb level for the avoidance of neurologic complica-
tions. By necessity, the recommendations of published con-
sensus guidelines are relatively non-specific, and state that it
is "not unreasonable to transfuse red cells in certain patients
with critical noncardiac end-organ ischemia whose Hb levels
are as high as 10 g/dl" [111]. Funding was recently secured
in the UK for a multi-center RCT comparing transfusion trig-
gers of 7.5 vs. 9 g/dl [92].
Traumatic brain injury
The majority of patients dying from severe TBI have histologic
evidence of ischemic damage [127]. Early global CBF reduc-
tions occur in many patients, often to levels that are consid-
ered to be in the ischemic range [128,129]. Reductions in
both jugular venous O2 saturation (SjvO2) and PbtO2 are not
only common, but their frequency and depth are predictive of
worse outcomes [130-133]. However, the fall in CBF may be
appropriate for a corresponding drop in metabolic rate
[134,135]. Recent studies using positron emission tomogra-
phy (PET) have suggested that although ischemia does occur,
it is less common than previously thought. Furthermore, much
of the 'metabolic distress' detected by multimodal monitoring
(SjvO2, PbtO2, and microdialysis parameters) is not necessarily
attributable to classical ischemia [39,134,135].
On the other hand, there appears to be a great deal of regional
heterogeneity in CBF and CMRO2 [136]. Even if the overall
ischemic brain volume is relatively small, certain vulnerable
regions may still benefit from enhanced O2 delivery [137]. As
with cardiac surgical patients, relatively extreme reductions in
Hb are likely to be deleterious. A recent animal model found
that although isovolemic hemodilution to Hb concentrations of
5 to 7 g/dl resulted in an overall increase in CBF, it produced
larger contusion volumes, more apoptosis, and lower PbtO2
[138].
Potentially beneficial physiologic effects of transfusion have
been shown in four studies of patients with severe TBI [139-
142], each of which demonstrated that PbtO2 increases fol-
lowing the administration of RBCs (Table 3) [139]. However,
this increment was inconsistent, relatively small and often of
questionable clinical importance. Of concern, in some cases
there was even a reduction in PbtO2. It is possible that some of
the variation in the cerebral effects of transfusion could be, in
part, attributable to the variable age of transfused blood. Leal-
Karkouti and 
colleagues [105]
10,949 Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Nadir 
intraoperative hct
Postoperative 
stroke (new 
persistent 
postoperative 
neurologic deficit) 
that was present 
on emergence 
from anesthesia
Each 1% hct 
reduction 
associated with 
OR = 1.1 for 
stroke (P = 0.002)
Habib and 
colleagues [106]
5000 Retrospective 
(prospective 
database)
Single-center
None Nadir 
intraoperative hct
Transient or 
permanent 
postoperative 
stroke 
(not further 
defined)
Risk of TIA or 
stroke 5.4% in 
quintile with 
lowest hct vs. 
1.3% in quintile 
with highest hct (P 
< 0.001)
DeFoe and 
colleagues [107]
6980 (CABG) Retrospective 
(prospective 
database)
Multi-center
Logistic 
regression
Nadir 
intraoperative hct
Intra- or 
postoperative 
stroke (new focal 
neurologic deficit 
which appears 
and is still at least 
partially evident 
more than 24 
hours after onset; 
occurs during or 
following CABG)
No statistically 
significant 
association 
between hct and 
stroke
Van 
Wermeskerken 
and colleagues 
[108]
2804 (CABG) Retrospective
Single-center
Logistic 
regression
Nadir 
intraoperative hct
Adverse 
neurologic 
outcomes: stroke, 
coma, or TIA; 
verified 
retrospectively by 
neurologist
No significant 
association 
between hct and 
outcome
CABG = coronary artery bypass grafting; CI = confidence interval; CNS = central nervous system; Hb = hemoglobin; hct = hematocrit; ICU = 
intensive care unit; OR = odds ratio; RCT = randomized controlled trial; TIA = transient ischemic attack; VR = valve replacement
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Table 2
Adult studies assessing the association between transfusion and the development of perioperative stroke or cognitive dysfunction 
among patients undergoing cardiac surgery
Study Patients Design and 
setting
Multivariable 
analysis
Exposure Outcome Main result
Brevig and 
colleagues [117]
2531 Retrospective 
(prospective 
database)
Single-center
None Any blood product 
transfusion
Postoperative 
CVA 
(not further 
defined)
Despite reduction 
in proportion of 
patients 
transfused over 
time (43% in 
2003 vs. 18% in 
2007), no change 
in proportion of 
patients with CVA 
(0.8 to 1.5%)
Ngaage and 
colleagues [118]
383 (≥80 years 
old)
Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Any blood product 
transfusion
Neurologic 
complications 
(confusion/
agitation, seizures, 
TIA, RIND, stroke, 
or coma)
Transfusion 
associated with 
neurologic 
complications (OR 
= 3.6 vs. no 
transfusion, P = 
0.003)
Murphy and 
colleagues [119]
8518 Retrospective
Single-center
Logistic 
regression and 
propensity scores
Any perioperative 
RBC transfusion
Composite of MI, 
stroke (permanent 
or transient), or 
renal failure
RBC transfusion 
was associated 
with composite 
outcome (OR = 
3.35 for 
transfusion vs. no 
transfusion; P < 
0.0001)
Whitson and 
colleagues [120]
2691 Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Any RBC 
transfusion
CVA 
(not further 
defined)
RBC transfusion 
was associated 
with CVA (OR = 
1.7, P = 0.01)
Norkiene and 
colleagues [121]
1367 Retrospective
Single-center
Logistic 
regression
Any RBC 
transfusion
Delirium (DSM-IV 
criteria)
Postoperative 
RBC transfusion 
was associated 
with delirium (OR 
= 4.6, P < 0.001)
Koch and 
colleagues [122]
11,963 (CABG) Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Total number of 
units of RBCs 
transfused
Focal or global 
neurologic deficits 
or death without 
awakening
RBC transfusion 
was associated 
with stroke (OR = 
1.73 for each unit 
RBCs; P < 
0.0001)
Stamou and 
colleagues [123]
49 JW patients Retrospective
Single-center
196 controls
Logistic 
regression and 
propensity scores
Any RBC 
transfusion
Nadir Hb not 
reported
Perioperative 
stroke
No statistically 
significant 
difference in risk 
of stroke between 
JWs refusing 
RBCs and 
transfused control 
patients
Karkouti and 
colleagues [105]
10,949 Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Total number of 
units of blood 
product
New perioperative 
persistent 
postoperative 
neurological 
deficit
Transfusion was 
associated with 
stroke (OR = 1.02 
for each unit 
RBCs; P = 0.01)
Bucerius and 
colleagues [124]
16,184 Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Any perioperative 
RBC transfusion
Temporary or 
permanent focal or 
global neurologic 
deficit
'High transfusion 
requirement' 
((≥1000 ml) was 
associated with 
stroke (OR = 
6.04; P < 0.0001)Available online http://ccforum.com/content/13/3/R89
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Noval and colleagues recently found that only those patients
having received RBCs less than 14 days old had a statistically
significant improvement in PbtO2 one hour after transfusion
[141]. Although these results are intriguing, they are too pre-
mature to influence clinical practice and require confirmation
in larger studies. Just because PbtO2 rises, does not necessar-
ily mean that CMRO2 has increased. On the contrary, Zygun
and colleagues found no improvement in cerebral lactate to
pyruvate ratio (LPR – a marker of ischemia and 'metabolic dis-
tress') in response to transfusion, despite an increment in
PbtO2 [142].
In a retrospective study of 169 patients with TBI, Carlson and
colleagues found nadir hematocrit levels to be associated with
a worse Glasgow Outcome Scale at hospital discharge. How-
ever, the association between RBC transfusion and poor out-
come was even stronger [143]. Other observational studies
have reached similar conclusions (Table 4) [144-151]. Unfor-
tunately, there are no large RCTs to guide practice at this time.
The TRICC trial enrolled only 67 patients with severe TBI
[150]. Although no statistically significant benefit from a liberal
transfusion strategy was observed, this subgroup was too
small to reach meaningful conclusions. Thus, the optimal use
of RBCs in patients with severe TBI remains unclear. A recent
survey found that practice across the USA is variable, and that
the majority of clinicians believe a threshold of 7 g/dl to be too
restrictive, especially in the presence of intracranial hyperten-
sion [27].
Subarachnoid hemorrhage
Narrowing of the cerebral vasculature (angiographic vasos-
pasm) complicates about two-thirds of cases of SAH. Vasos-
pasm most often emerges between days 3 and 14 after SAH
and is the most important cause of secondary brain injury [87].
Evidence of cerebral infarction that was not present initially is
observed in as many as 50 to 70% of survivors using magnetic
resonance imaging (MRI) [152,153]. Unlike other forms of
stroke, the predictable risk of vasospasm and cerebral
ischemia provides a unique opportunity for the provision of
neuroprotection prior to the insult.
Three studies have assessed the association between daily
Hb concentrations and eventual neurologic outcome [154-
156]. Each of these demonstrated that patients with an unfa-
vorable outcome consistently have lower Hb levels throughout
much of the first two weeks in hospital (Table 5). The degree
of decrement in Hb levels over time was also highly predictive
of outcome [154]. Despite the use of multivariable analyses,
there were numerous potentially confounding variables that
could not be adjusted for. For example, patients who are
'sicker' tend to have more blood drawn for laboratory tests,
have more invasive procedures performed, and tend to receive
more intravenous fluids, all of which could contribute to lower
Hb concentrations. Thus, the association between lower Hb
and poor outcome has not conclusively been proven to be
causative.
As in other settings, several studies have also shown a strong
association between transfusion and unfavorable outcomes
following SAH (Table 5) [28,157-160]. One unconfirmed
report suggested that the use of RBCs could contribute to the
development of cerebral vasospasm, perhaps by promoting
inflammation or depleting endogenous NO supplies [160]. A
recent observational study found no difference in complica-
tions based on the transfusion of older (>21 days) compared
with newer (≤21 days) units of blood, although this assess-
ment was based on only 85 transfused patients [28].
Hemodilution, together with hypervolemia and hypertension,
has been used as part of 'triple H therapy', a therapeutic strat-
egy to improve CBF in patients with vasospasm [161]. One
study used 133Xenon injections to assess global CBF in eight
patients with SAH. As expected, isovolemic hemodilution from
a mean Hb of 11.9 to 9.2 g/dl produced an increase in global
CBF and a reduction in cerebral vascular resistance. However,
the increase in CBF was not sufficient to overcome the reduc-
tion in CaO2, such that global O2 delivery fell and ischemic
brain volume actually increased [162]. Complimentary findings
were subsequently reported by Muench and colleagues, who
used aggressive volume expansion on days 1, 3, and 7, which
produced a concomitant reduction in Hb concentration rang-
ing from of 1.3 to 2.0 g/dl. Although this intervention consist-
ently produced a small increment in CBF, it actually caused a
proportionally larger decline in PbtO2  (Table 3) [163].
More recently, Dhar and colleagues assessed the effects of
transfusion in patients with SAH using PET [164]. PET scans
were performed before and after the administration of one unit
of RBCs to patients with pre-transfusion Hb concentrations
less than 10 g/dl. Although no change in CMRO2  was
D'Ancona and 
colleagues [125]
9916 (CABG) Retrospective 
(prospective 
database)
Single-center
Logistic 
regression
Any blood product 
transfusion
New temporary or 
permanent, focal 
or global 
neurologic deficit
Transfusion was 
associated with 
stroke (OR = 1.59 
vs. no transfusion; 
P = 0.002)
CABG = coronary artery bypass grafting; CVA = cerebrovascular accident; Hb = hemoglobin; JW = Jehovah's Witness; MI = myocardial 
infarction; OR = odds ratio; RBC = red blood cell; RIND = reversible ischemic neurologic deficit; TIA = transient ischemic attack.
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Table 3
Clinical studies assessing the impact of anemia or RBC transfusions on PbtO2 and other physiologic parameters in brain-injured 
patients
Study Patients Design Baseline Intervention Main findings
Smith and colleagues 
[139]
23 TBI
12 SAH
Retrospective 
(prospective 
database)
Hb = 8.7 g/dl
PbtO2 = 24.4 mmHg
Any RBC transfusion 
(number of units not 
specified a priori; 
80% received ≥1 unit; 
mean Hb increased to 
10.2 g/dl)
General transfusion 
threshold Hb <10 g/
dl or hct <30% 
(no protocol)
- Mean increment in 
PbtO2 3.2 mmHg 
(15%)
- Increment not 
related to baseline 
PbtO2
- PbtO2 decreased in 
9/35 patients (26%)
Leal-Noval and 
colleagues [140]
51 TBI Prospective 
observational
Hb = 9.0 g/dl
PbtO2 = 24.4 mmHg
1 or 2 units RBCs 
(number of units not 
specified a priori; 
52% received 2 units; 
mean Hb increased to 
10.6 g/dl)
General transfusion 
threshold Hb <10 g/
dl (no protocol)
- Mean increment in 
PbtO2 3.8 mmHg 
(16%)
- Increment larger at 
lower baseline PbtO2
- PbtO2 decreased in 
13/51 patients (25%)
Leal-Noval and 
colleagues [141]
66 TBI (males) Prospective 
observational
Hb = 8.9 g/dl
PbtO2 = 21.3 to 26.2 
mmHg
1 or 2 units RBCs 
number of units not 
specified a priori; 
59% received 2 units; 
mean Hb increased to 
10.2 g/dl)
General transfusion 
threshold Hb <9.5 g/
dl (no protocol)
- Newer units of blood 
(≤14 days) resulted in 
greater mean 
increment in PbtO2 
(3.3 mmHg (16%) vs. 
2.1 mmHg (8%))
- PbtO2 decreased 
only in patients 
receiving older blood 
(>19 days)
Zygun and colleagues 
[142]
30 TBI Prospective RCT Hb = 8.2 g/dl
PbtO2 = 18.8 mmHg
Randomized to 
transfusion thresholds 
of 8, 9, or 10 g/dl; 2 
units RBCs 
administered over 2 
hours (mean Hb 
increased to 10.1 g/
dl)
- Mean increment in 
PbtO2 2.2 mmHg 
(12%)
- Increment in PbtO2 
most prominent when 
LPR >25
- PbtO2 decreased in 
13/30 patients (43%)
- No effect on SjvO2 or 
microdialysis 
parameters
Ekelund and 
colleagues [162]
8 SAH 
(TCD-vaso-spasm)
Prospective 
interventional
Hb = 11.9 g/dl Isovolemic 
hemodilution 
(venesection with 
infusion of dextran 70 
and 4% albumin) to 
mean Hb of 9.2 g/dl
- Outcomes (using 
133Xenon and 
SPECT):
- Increased global 
CBF 
(52.3 to 58.6 ml/100 
g/min)
- Reduced cerebral 
vascular resistance
- Reduced oxygen 
delivery
- Increased ischemic 
brain volume
Muench and 
colleagues [163]
10 SAH Prospective 
interventional
Hb = 10.6 g/dl
PbtO2 = 24.8 mmHg
Volume expansion 
with HES ± 
crystalloid to achieve 
ITBVI >1000 ml/m2; 
this produced a 
decline in Hb of 1.3 to 
2.0 g/dl 
(on various days)
- Although 
hypervolemia/
hemodilution 
produced a slight 
increment in CBF, 
PbtO2 decreased by 
an average of 0 to 5 
mmHg
- Only induced 
hypertension was 
consistently effective 
at raising PbtO2Available online http://ccforum.com/content/13/3/R89
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observed, OEF dropped from 49 to 41%. Thus, it is possible
that in vulnerable regions of the brain with relatively high OEF,
RBC transfusions could help avoid irreversible infarction.
Another recent study of 20 SAH patients found Hb concentra-
tions less than 9 g/dl to be associated with lower PbtO2 and
higher LPR [165].
In summary, there is now extensive data to suggest that even
moderate degrees of anemia are associated with worse phys-
iologic parameters and clinical outcomes in patients with SAH.
However, it is not clear that the use of RBC transfusions can
modify these associations. An adequately powered, RCT com-
paring different transfusion thresholds is urgently required,
especially in light of the vulnerability of these patients to
delayed cerebral ischemia and the frequency with which they
develop anemia.
Ischemic stroke
Because of the known inverse relation between hematocrit
and CBF, there has long been interest in the clinical use of
hemodilution in the management of acute ischemic stroke
[166]. Some studies have suggested that relatively high Hb
concentrations may predispose to the development of strokes
[167-173], as well as contribute to worse outcomes when cer-
* Dhar and colleagues 
[164]
8 SAH Prospective 
interventional
Hb = 8.7 g/dl One unit RBCs (mean 
Hb increased to 9.9 
g/dl)
- Outcomes assessed 
using PET:
- No significant 
change in CBF
- Reduced O2 
extraction ratio (49 to 
41%; P = 0.06)
- No significant 
change in CMRO2
- Reduction in oxygen 
extraction ratio 
observed also in 
territories with 
vasospasm and low 
oxygen delivery
Oddo and colleagues 
[165]
20 SAH Retrospective 
(prospective 
database)
Not applicable None - Hb <9 g/dl 
associated with 
higher risk of PbtO2 
<20 mmHg (OR 7.2, 
P < 0.01) and LPR 
>40 (OR 4.2, P = 
0.02)
Chang and 
colleagues [237]
27 TBI Retrospective Not applicable None - 13.7% of PbtO2 
readings <20 mmHg
- No significant 
association between 
PbtO2 and Hb
Naidech and 
colleagues [238]
6 SAH Prospective 
observational
Not reported 14 RBC transfusions 
(no protocol)
- Hb correlated with 
cerebral oximetry 
(rO2)
- rO2 increased 
following 11/14 
transfusions, but not 
statistically significant
Sahuquillo and 
colleagues [239]
28 TBI Prospective Not applicable None - Critical LOI 
(suggestive of 
ischemia/infarction) 
associated with lower 
Hb 
(11.7 g/dl vs. 13.1 g/
dl)
Cruz and colleagues 
[240]
62 TBI Retrospective 
(prospective data)
Not applicable None - Cerebral extraction 
of oxygen was highest 
when Hb <10 g/dl
* published only as abstract.
CBF = cerebral blood flow; CMRO2 = cerebral metabolic rate; Hb = hemoglobin; HES = hydroxyethyl starch; ITBVI = intrathoracic blood volume 
index; LOI = jugular venous lactate:oxygen index; LPR = lactate:pyruvate ratio; PbtO2 = brain tissue oxygen tension; PET = positron emission 
tomography; RBC = red blood cell; RCT = randomized controlled trial; rO2 = cerebral oximetry; SAH = subarachnoid hemorrhage; SjvO2 = jugular 
venous oxygen saturation; SPECT = single photon emission computed tomography; TBI = traumatic brain injury; TCD = transcranial Doppler.
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Table 4
Clinical studies assessing the association between hemoglobin concentrations, anemia, or transfusion and subsequent outcomes 
among patients with traumatic brain injury
Study Patients Design and 
setting
Exposure Pre-transfusion 
Hb or Hct
Analysis 
(variables)
Main result
Carlson and 
colleagues [143]
169 Retrospective
Single-center
- Number of days 
hct <30%
- Nadir hct
- RBC transfusion
Not reported Linear regression 
assessing GOS 
as continuous 
variable
- Number of RBC 
units, lowest hct 
associated with 
worse discharge 
outcome
- Number of days 
hct <30% 
associated with 
better outcome
‡Steyerberg and 
colleagues [144]
3554 Post hoc analysis 
of several RCTs
Multi-center
Admission Hb 
(median 12.7 g/dl)
Not relevant Logistic 
regression 
(10 covariates)
- Lower Hb 
associated with 
poor 3 to 6 month 
outcome (OR for 
14.3 g/dl vs. 10.8 
g/dl = 0.78, 0.70 
to 0.87)
- Laboratory 
variables (Hb and 
glucose) improved 
prognostic models
Duane and 
colleagues [145]
788 Retrospective
Single-center
Hb in first 72 
hours
RBC transfusion
Not reported Logistic 
regression (age, 
ISS, total blood 
products)
- Minimum 
hemoglobin in first 
72 hours 
associated with 
hospital mortality 
(OR = 0.86, 0.73 
to 1.0 per g/dl 
increment)
- RBC 
transfusions not 
associated with 
mortality, but with 
nosocomial 
infection
Salim and 
colleagues [146]
1150 Retrospective 
(prospective 
database)
Single-center
Anemia (Hb <9 g/
dl; occurred in 
46%) and RBC 
transfusion (46%)
Not reported Logistic 
regression 
(10 covariates)
- RBC transfusion 
associated with 
hospital mortality 
(OR = 2.2, P = 
0.004) and 
complications (OR 
= 3.7, P < 
0.0001)
- Anemia 
associated with 
adverse outcomes 
only when 
transfusion not 
included in model
George and 
colleagues [147]
82 
(Hb 8.0 to 10.0 g/
dl)
Retrospective
Single-center
RBC transfusion 
(52%)
8.6 g/dl Cox proportional 
hazard regression 
(age, motor GCS, 
blood ethanol, 
lowest Na+, 
complications)
RBC transfusion 
predicted mortality 
(P < 0.05)
‡Van Beek and 
colleagues [148]
3872 Post hoc analysis 
of several RCTs
Multi-center
Admission Hb Not relevant Logistic 
regression (age, 
motor score, pupil 
reactivity)
- Lower Hb 
associated with 
higher risk of 
death/vegetative 
state at 3 to 6 
months (OR = 
0.69, 0.60 to 
0.81, for 75th 
percentile vs. 25th 
percentile)Available online http://ccforum.com/content/13/3/R89
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ebral ischemia occurs [174-177]. It is conceivable that
increased viscosity could have a particularly deleterious effect
on microvascular flow through the ischemic penumbra. Con-
sistent with this notion, Allport and colleagues performed
serial MRI scans in 64 stroke patients and found that a higher
baseline hematocrit was independently associated with infarct
growth and less chance of successful reperfusion [178].
The deleterious association with a higher hematocrit has, how-
ever, been inconsistent and largely observed at levels in
excess of 45% (Table 6). Indeed, several studies have shown
a U-shaped relation where low hematocrit levels are also asso-
ciated with larger infarct size and worse outcomes
[175,177,179-184]. The lowest risk of stroke and the best
outcomes have generally been observed with mid-range
hematocrit levels of about 42 to 45% [172,175]. This range
was also supported by a study using 133Xe to assess CBF in
stroke patients, with the finding that cerebral O2 delivery was
optimized at a hematocrit level of 40 to 45% [185]. Con-
versely, several animal studies have suggested that cerebral
O2 delivery and neuroprotection are optimized at slightly lower
hematocrit or Hb values, in the range of 30 to 36% and 10 to
12 g/dl, respectively [58,186,187]. Greater degrees of
hemodilution consistently appear to be deleterious [188].
Some case reports have even described patients with rela-
tively stenotic cerebral vessels who may have developed
ischemic strokes directly attributable to anemia [189-191].
Several RCTs and a meta-analysis have not shown any clear
benefit to using hemodilution as a therapeutic strategy in acute
ischemic stroke [192]. However, there was a great deal of het-
erogeneity in the methodology of these studies (timing of treat-
ment, specific type and dose of plasma expander, target
hematocrit). Although each study deliberately produced
reductions in hematocrit with the use of colloids and/or phle-
botomy, the reductions were relatively modest, generally not
beyond 37 to 38% [192-196].
More recently, several animal studies and phase II human trials
have suggested that hemodilution with relatively high doses of
albumin may reduce infarct size and enhance the efficacy of
thrombolytic therapy [197-200]. It is likely that this effect was
observed, in part, because of the unique properties of albumin,
rather than only hemodilution. In a phase II dose-finding study,
the reduction in hematocrit induced by the highest doses of
albumin averaged 6 to 10% [198,199].
In summary, there is currently no routine role for hemodilution
in the management of acute ischemic stroke. Whether trans-
fusing anemic stroke patients with Hb concentrations lower
than 9 to 11 g/dl is beneficial has not been well evaluated.
Intracerebral hemorrhage
There has been controversy regarding the importance of cere-
bral ischemia in causing secondary brain injury after ICH. Early
studies had suggested that an expanding intracerebral
hematoma could cause mechanical compression and vaso-
constriction of the surrounding vasculature, thereby producing
a 'perihematomal penumbra' [201-203]. Imaging with PET, CT
perfusion scans, and MRI have confirmed that the majority of
patients with ICH have a surrounding rim of hypoperfusion
[91,204-206]. The biochemistry of this region appears to be
similar to that of traumatic cerebral contusions [207]. How-
ever, OEF is not increased in the perihematomal tissues, sug-
gesting that this hypoperfusion is due to reduced cerebral
metabolism, rather than true ischemia [91]. Thus, mild reduc-
tions in Hb concentration are unlikely to have a major impact
in contributing to neuronal death. Nevertheless, it remains
Schirmer-
Makalsen and 
colleagues [149]
133 Retrospective
Single-center
Hb ever <8 g/dl 
(22%)
Not reported Logistic 
regression 
(10 covariates)
A single Hb <8 g/
dl did not predict 
adverse outcome
McIntyre and 
colleagues [150]
67 Post hoc analysis 
of RCT
Multi-center
Comparison of 
transfusion 
thresholds of 7.0 
g/dl vs. 10.0 g/dl
Not reported Logistic 
regression (age, 
APACHE II, PAC 
use)
- 30-day mortality 
17% in restrictive 
group vs. 13% in 
liberal group (P = 
0.64)
- Development of 
MOD and ICU 
LOS similar in 
both groups
Robertson and 
colleagues [151]
102 Prospective
Single-center
Hb at time of CBF 
determination
Not reported Logistic 
regression (age, 
CBF, GCS, CPP, 
CMRO2)
- Lower Hb 
associated with 
unfavorable GOS 
after 3 months
‡ Based, in part, on same datasets
APACHE = Acute Physiology and Chronic Health Evaluation; CBF = cerebral blood flow; CMRO2 = cerebral metabolic rate; CPP = cerebral 
perfusion pressure; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; Hb = hemoglobin; hct = hematocrit; ICU = intensive care 
unit; ISS = injury severity score; LOS = length of stay; MOD = multiple organ dysfunction; OR = odds ratio; PAC = pulmonary artery catheter; 
RBC = red blood cell; RCT = randomized controlled trial.
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Table 5
Clinical studies assessing the association between hemoglobin concentrations, anemia, or transfusion and subsequent outcomes 
among patients with aneurysmal subarachnoid hemorrhage
Study Patients Design and 
setting
Exposure Mean pre-
transfusion 
Hb/Hct
Analysis (variables) Main result
‡Kramer and 
colleagues 
[28]
245 Retrospective
Single-center
- Anemia 
(nadir Hb <10 g/dl)
- RBC transfusion 
(35%)
9.5 g/dl
No 
transfusion 
protocol
Logistic regression 
(WFNS score, age, 
vasospasm, modified 
Fisher score)
- Anemia and transfusion 
associated with poor 6 week 
outcome 
(association stronger for 
transfusion)
- RBCs associated with 
nosocomial infection
- Age of blood not associated 
with complications
‡Kramer and 
colleagues 
[154]
245 Retrospective
Single-center
Daily nadir Hb over 
2 weeks
9.5 g/dl
No 
transfusion 
protocol
GEE to account for 
correlated data (WFNS 
score, age, vasospasm, 
modified Fisher score)
- Hb and decline in Hb over time 
predict poor outcome
- Association between Hb and 
outcome stronger among high 
grade patients
†Naidech and 
colleagues 
[155]
611 Retrospective 
(prospective 
database)
Single-center
- Mean and nadir 
Hb over 2 weeks
- 35% transfused
Not reported
No 
transfusion 
protocol
Multinomial regression 
(Hunt-Hess, age, cerebral 
infarction)
Higher nadir (but not mean) Hb 
associated with better outcome 
after 3 months (OR = 0.83 per 
10 g/dl increase; P = 0.04)
Naidech and 
colleagues 
[156]
103 Retrospective 
(prospective 
database)
Single-center
- Mean Hb over 2 
weeks
- 47% transfused
9.2 g/dl
No 
transfusion 
protocol
Logistic regression 
(Hunt-Hess, age, 
angiographic vasospasm)
Higher 2 week mean Hb 
associated with better outcome 
at discharge (OR = 0.57 per 10 
g/dl increase; P = 0.04)
Tseng and 
colleagues 
[157]
160 Post hoc 
analysis 2 
RCTs)
Single-center
RBC transfusion 
(19%)
Not reported Logistic regression (age, 
WFNS, IVH, 
postoperative deficits, 
sepsis, DIDs)
- Transfusion associated with 
poor outcome at discharge (OR 
= 4.5, P = 0.04) but not 6 
months
- More colloid use predicted 
lower hct and need for 
transfusion
†Wartenberg 
and 
colleagues 
[158]
576 Retrospective 
(prospective 
database)
Single-center
Anemia (Hb <9 g/
dl treated with 
transfusion; 36% of 
cohort)
Not reported
No 
transfusion 
protocol
Logistic regression 
(Hunt-Hess, age, cerebral 
infarction, re-bleeding, 
aneurysm size >10 mm)
Anemia associated with worse 3 
month outcome (OR = 1.8; P = 
0.02)
* DeGeorgia 
and 
colleagues 
[159]
166 Retrospective
Single-center
RBC Transfusion 
(49%)
Not reported
No 
transfusion 
protocol
Logistic regression 
(Hunt-Hess, APACHE II)
Transfusion associated with 
worse outcome at discharge 
among patients with vasospasm, 
not without 
(OR = 2.9, CI = 1.1 to 7.8)
Smith and 
colleagues 
[160]
441 Retrospective 
(prospective 
database)
Single-center
RBC transfusion 
(61%)
Intra-
operative: 
39.6%
Post-
operative: 
32.0%
No 
transfusion 
protocol
Logistic regression 
(Hunt-Hess, Fisher, 
smoking, intra-operative 
rupture, delay to surgery)
- Intraoperative transfusion 
associated with poor 6 month 
outcome 
(OR = 2.4, CI = 1.3 to 4.5)
- Postoperative transfusion 
associated with angiographic 
vasospasm (OR = 1.7, CI = 1.0 
to 2.8))
‡ & †: studies used same datasets; *: published only as abstract
APACHE = Acute Physiology and Chronic Health Evaluation; CI = 95% confidence intervals; DID = delayed ischemic deficit; GEE = generalized 
estimating equation; Hb = hemoglobin; hct = hematocrit; IVH = intraventricular hemorrhage; OR = odds ratio; RBC = red blood cell; RCT = 
randomized controlled trial; WFNS = World Federation of Neurological Surgeons score.Available online http://ccforum.com/content/13/3/R89
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Table 6
Studies assessing the association between hemoglobin concentrations or anemia and subsequent clinical outcomes among 
patients with acute ischemic stroke
Study Patients Design and 
setting
Exposure Outcome Main result Comment
Sacco and 
colleagues [174]
3481 ischemic 
stroke
Retrospective 
(prospective data-
base)
Multi-center
Baseline hct 
(patients divided 
into quartiles)
Death at 28 days Hct >46% 
associated with 
death, but only 
among women
Hct ≤40% 
represented 
lowest quartile; 
effects of more 
extreme anemia 
not reported
Diamond and 
colleagues [175]
1012 ischemic 
stroke
Retrospective
Single-center
Baseline hct
Median 41%; 
inter-quartile 
range 38 to 44%
Discharge home 
(rather than 
nursing facility)
High and low hct 
associated with 
worse outcome 
(U shaped curve)
Optimal hct 45%
Only 2% of 
patients had hct 
<30% at time of 
their stroke
Lowe and 
colleagues [177]
270 ischemic 
stroke
Retrospective
Single-center
Baseline hct Death in hospital Patients with high 
hct (≥50%) had 
higher mortality 
(66 to 71%)
Elderly (≥75) with 
hct <40% also 
had higher 
mortality (65%)
Allport and 
colleagues [178]
64 hemispheric 
ischemic stroke
Prospective
Single-center
Baseline hct
Median 42%; 
range 33 to 48%
Reperfusion, 
infarct growth on 
serial MRI
Higher hct 
associated with 
less reperfusion 
(OR = 0.53, P < 
0.0001) and more 
infarct growth (OR 
= 1.26, P < 0.05)
This was a study 
of the effects of 
high hct; few 
patients were 
anemic
†Huang and 
colleagues [179]
774 ischemic 
stroke
Prospective
Single-center
Anemia (Hb <13 
g/dl for men, <12 
g/dl for women) 
(21%)
Death and mRS 
≥3 at 3 years
Anemic patients 
more likely to die 
(OR = 2.2, P = 
0.02) and to have 
a poor 
neurological 
outcome (67% vs. 
60%, P = 0.07)
Numerous 
potential 
confounders not 
adjusted for; 
severity of anemia 
not well 
characterized
†Huang and 
colleagues [180]
66 ischemic 
stroke 
(complicating ICA 
occlusion)
Prospective
Single center
Anemia (Hb <13 
for men, <12 for 
women)
Death or recurrent 
stroke at 2 years
Anemia 
associated with 
death or recurrent 
stroke at 2 years 
(OR = 5.1, P = 
0.012)
Numerous 
potential 
confounders not 
adjusted for; 
severity of anemia 
not well 
characterized
Nybo and 
colleagues [181]
250 ischemic 
stroke
Retrospective
Single-center
Anemia (Hb <13 
g/dl for men, <12 
g/dl for women) 
(15%)
Death at 6 months Anemia 
associated with 
greater risk of 
death 
(OR = 3.6, CI = 
1.4 to 9.3)
Numerous 
potential 
confounders not 
adjusted for; 
severity of anemia 
not well 
characterized
Bhatia and 
colleagues [182]
116 ischemic or 
hemorrhagic 
stroke
Retrospective
Single-center
Baseline Hb Death at 30 days Hb not associated 
with risk of death
Degree of anemia 
relatively mild
Wade and 
colleagues [183]
1377 
symptomatic 
cerebrovascular 
disease
Retrospective 
(post hoc review 
of prospective 
RCT)
Multi-center
Hb >15 g/dl vs. 
≥15 g/dl at study 
entry
Stroke Patients with Hb 
≥15 had similar 
outcomes to 
patients with Hb 
<15 g/dl
This was a study 
of the effects of 
high Hb; few 
patients were 
anemic
LaRue and 
colleagues [184]
2077 ischemic or 
hemorrhagic 
stroke
Retrospective 
(prospective 
database)
Multi-center
Baseline hct 
(patients divided 
into quartiles)
Death in hospital Hct not predictive 
of death (neither 
when high nor 
low)
Neurologic 
outcomes (other 
than death) not 
reported
CI = confidence interval; Hb = hemoglobin; hct = hematocrit; ICA = internal carotid artery; MRI = magnetic resonance imaging; mRS = modified 
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uncertain whether perihematomal tissues tolerate anemia as
well as healthy brain.
Use of hemoglobin-based blood substitutes
Hb-based blood substitutes (HBBS) have theoretical advan-
tages over other fluids in the resuscitation of neurocritical care
patients, because they have the potential to achieve the CBF-
enhancing effects of hemodilution, while concomitantly main-
taining, or even raising, CaO2. Several animal studies per-
formed in the setting of experimental ischemic stroke, TBI, and
SAH-induced vasospasm have supported this concept [208-
221]. Alternatively, free Hb may also have numerous deleteri-
ous effects, probably mediated, in large part, by scavenging of
NO [222]. Although not all products are identical, a recent
meta-analysis of RCTs suggested that their use is associated
with an increased risk of death and myocardial infarction
[223]. One phase II RCT involving 85 patients with ischemic
stroke reported worse neurological outcomes with the use of
diaspirin cross-linked Hb [224]. Of the five RCTs involving
trauma patients, none specifically assessed the subgroup of
patients with TBI, although the largest study reported no sta-
tistically significant interaction between HBBS and admission
Glasgow coma scale on mortality [225-229]. Two of the three
RCTs in the setting of cardiac surgery reported the occur-
rence of perioperative stroke; there were no differences
between HBBS-treated and control patients [230,231]. Thus,
although the use of HBSS in neurocritical care should be fur-
ther investigated, there is currently no role for the routine use
of these products.
Conclusions
Anemia is common in neurocritical care patients, is associated
with worse outcomes, and should be avoided as much as pos-
sible with blood conservation strategies. Although Hb concen-
trations as low as 7 g/dl are well tolerated by most critically ill
patients [25], there is ample data from animal studies, as well
as human physiologic and observational studies to suggest
that such a severe degree of anemia could be harmful in the
brain-injured patient. Thus, in our practice, we frequently trans-
fuse selected patients with Hb concentrations less than 8 to 9
g/dl. However, because allogeneic RBCs have multiple poten-
tially deleterious effects, it cannot be assumed that the use of
transfusions to 'correct' Hb levels alters the association
between anemia and adverse outcomes. The impact of the
duration of blood storage on the neurologic implications of
transfusion requires further investigation. Unfortunately, exist-
ing guidelines provide little guidance to clinicians in deciding
when to transfuse anemic stroke and neurocritical care
patients [232-236]; clearly, RCTs are needed.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AHK was responsible for the conception and design of the
study, the analysis and interpretation of the data, and the draft-
ing and revision of the manuscript. DAZ was responsible for
the analysis and interpretation of data, and the revision of the
manuscript. Both authors approved the final version of the
manuscript.
References
1. Al Thanayan E, Bolton C, Hichici D, Savard M, Teitelbaum J, Young
B, Zygun D: Neurocritical care in Canada: evolving streams in
a new discipline.  Can J Neurol Sci 2008, 35:405-408.
2. Elf K, Nilsson P, Enblad P: Outcome after traumatic brain injury
improved by an organized secondary insult program and
standardized neurointensive care.  Crit Care Med 2002,
30:2129-2134.
3. Patel HC, Menon DK, Tebbs S, Hawker R, Hutchinson PJ, Kirk-
patrick P: Specialist neurocritical care and outcome from head
injury.  Intensive Care Med 2002, 28:547-553.
4. Miller JD, Sweet RC, Narayan R, Becker DP: Early insults to the
injured brain.  JAMA 1978, 240:439-442.
5. Chesnut RM, Marshall LF, Klauber MR, Blunt BA, Baldwin N,
Eisenberg HM, Jane JA, Marmarou A, Foulkes MA: The role of
secondary brain injury in determining outcome from severe
head injury.  J Trauma 1993, 34:216-222.
6. McHugh GS, Engel DC, Butcher I, Steyerberg EW, Lu J, Mushku-
diani N, Hernandez AV, Marmarous A, Maas AI, Murray GD: Prog-
nostic value of secondary insults in traumatic brain injury:
results from the IMPACT study.  J Neurotrauma 2007,
24:287-293.
7. Henzler D, Cooper DJ, Tremayne AB, Rossaint R, Higgins A: Early
modifiable factors associated with fatal outcome in patients
with severe traumatic brain injury: a case control study.  Crit
Care Med 2007, 35:1027-1031.
8. Iron Deficiency Anemia Assessment, Prevention, and Control:
A guide for programme managers   [http://whqlibdoc.who.int/
hq/2001/WHO_NHD_01.3.pdf]
9. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D,
Pearl RG: Nutritional deficiencies and blunted erythropoietin
response as causes of anemia of critical illness.  J Crit Care
2001, 16:36-41.
10. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A,
Meier-Hellmann A, Nollet G, Peres-Bota D: Anemia and blood
Key messages
￿  Despite an increment in cerebral blood flow, even mod-
erate reductions in Hb concentration lead to less overall 
cerebral oxygen delivery, resulting in lower PbtO2 and 
'metabolic distress' (higher OEF and LPR).
￿  Although the relation has not been proven with certainty 
to be causative, anemia is consistently associated with 
worse outcomes among neurocritical care patients.
￿  Despite some beneficial physiologic effects (increased 
PbtO2 and reduced OEF), it remains uncertain whether 
transfusion can improve cerebral metabolism and help 
salvage tenuous 'penumbral' brain tissue, thereby 
improving neurologic recovery.
￿  Although a transfusion threshold of 7 g/dl is safe in 
many general critical care patients, it remains unclear if 
this is also true in neurocritical care patients.
￿  The duration of red blood cell storage may have implica-
tions on the cerebral consequences of transfusion.Available online http://ccforum.com/content/13/3/R89
Page 17 of 22
(page number not for citation purposes)
transfusion in critically ill patients.  JAMA 2002,
288:1499-1407.
11. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E,
MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: The CRIT Study:
Anemia and blood transfusion in the critically ill – current prac-
tice in the United States.  Crit Care Med 2004, 32:39-52.
12. Nguyen BV, Bota DP, Melot C, Vincent JL: Time course of hemo-
globin concentrations in nonbleeding intensive care unit
patients.  Crit Care Med 2003, 31:406-410.
13. Scharte M, Fink MP: Red blood cell physiology in critical illness.
Crit Care Med 2003, 31:S651-657.
14. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Mélot C, Vin-
cent JL: Erythropoietin response in blunted in critically ill
patients.  Intensive Care Med 1997, 23:159-162.
15. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ,
Wiel A van de: Response of erythropoiesis and iron metabo-
lism to recombinant human erythropoietin in intensive care
unit patients.  Crit Care Med 2000, 28:2773-2778.
16. Darveau M, Denault AY, Blais N, Notebaert E: Bench-to-bedside
review: iron metabolism in critically ill patients.  Crit Care 2004,
8:356-362.
17. Corwin HL, Krantz SB: Anemia of the critically ill: "Acute" ane-
mia of chronic disease.  Crit Care Med 2000, 28:3099.
18. Walsh TS, Saleh EE: Anemia during critical illness.  Br J Anesth
2006, 97:278-291.
19. Smoller BR, Kruskall MS: Phlebotomy for diagnostic laboratory
tests in adults. Patterns of use and effect on transfusion
requirements.  N Engl J Med 1986, 314:1233-1235.
20. Tarpey J, Lawler PG: Iatrogenic anemia? A survey of venesec-
tion in patients in the intensive therapy unit.  Anaesthesia 1990,
45:396-398.
21. Zimmerman JE, Seneff MG, Sn X, Wagner DP, Knaus WA: Evalu-
ating laboratory usage in the intensive care unit: patient and
institutional characteristics that influence frequency of blood
sampling.  Crit Care Med 1997, 25:737-748.
22. Berezina TL, Zaets SB, Kozhura VL, Novoderzhkina IS, Kirsanova
AK, Deitch EA, Machiedo GW: Morphologic changes of red
blood cells during hemorrhagic shock replicate changes of
aging.  Shock 2001, 15:467-470.
23. Walsh TS, Garrioch M, Maciver C, Lee RJ, MacKirdy F, McClelland
DB, Kinsella J, Wallis C: Red cell requirements for intensive
care units adhering to evidence-based transfusion guidelines.
Transfusion 2004, 44:1405-1411.
24. French CJ, Bellomo R, Finfer SR, Lipman J, Chapman M, Boyce
NW: Appropriateness of red blood cell transfusion in Austral-
asian intensive care practice.  Med J Aust 2002, 177:548-551.
25. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C,
Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicenter,
randomized, controlled clinical trial of transfusion require-
ments in critical care. Transfusion Requirements in Critical
Care Investigators, Canadian Critical Care Trials Group.  N
Engl J Med 1999, 340:409-417.
26. Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet
T, Gauvin F, Collet JP, Toledano BJ, Robillard P, Joffe A, Biarent D,
Meert K, Peters MJ: TRIPICU Investigators; Canadian Critical
Care Trials Group; Pediatric Acute Lung Injury and Sepsis
Investigators Network. Transfusion strategies for patients in
pediatric intensive care units.  N Engl J Med 2007,
356:1609-1619.
27. Sena MJ, Rivers RM, Muizelaar JP, Battistella FD, Utter GH: Trans-
fusion practices for acute traumatic brain injury: a survey of
physicians at US trauma centers.  Intensive Care Med 2009,
35:480-488.
28. Kramer AH, Gurka MJ, Nathan B, Dumont AS, Kassell NF, Bleck
TP: Complications associated with anemia and blood transfu-
sion in patients with aneurismal subarachnoid hemorrhage.
Crit Care Med 2008, 36:2070-2075.
29. Pendem S, Rana S, Manno EM, Gajic O: A review of red cell
transfusion in the neurological intensive care unit.  NeuroCrit
Care 2006, 4:63-67.
30. Vavilala MS, Lee LA, Lam AM: Cerebral blood flow and vascular
physiology.  Anesthesiol Clin North America 2002, 20:274-264.
31. Marshall RS: The functional relevance of cerebral hemodynam-
ics: why blood flow matters to the injured and recovering brain.
Curr Opin Neurol 2004, 17:705-709.
32. Udomphorn Y, Armstead WM, Vavilala MS: Cerebral blood flow
and autoregulation after pediatric traumatic brain injury.  Pedi-
atr Neurol 2008, 38:225-234.
33. Hatcher JD, Chiu LK, Jennings DB: Anemia as a stimulus to aor-
tic and carotid chemoreceptors in the cat.  J Appl Physiol 1978,
44:696-702.
34. Chapler CK, Cain SM: The physiologic reserve in oxygen carry-
ing capacity: studies in experimental hemodilution.  Can J
Physiol Pharmacol 1985, 64:7-12.
35. Habler OP, Kleen MS, Podtschaske AH, Hutter JW, Tiede M, Kem-
ming GI, Welte MV, Corso CO, Messmer KF: The effect of acute
normovolemic hemodilution (ANH) on myocardial contractility
in anesthetized dogs.  Anesth Analg 1996, 83:451-458.
36. Murray JF, Escobar E, Rapaport E: Effects of blood viscosity on
hemodynamic responses in acute normovolemic anemia.  Am
J Physiol 1969, 216:638-642.
37. Fowler NO, Holmes JC: Blood viscosity and cardiac output in
acute experimental anemia.  J Appl Physiol 1975, 39:453-456.
38. Hebert PC, Linden P Van der, Biro G, Hu LQ: Physiologic
aspects of anemia.  Crit Care Clin 2004, 20:187-212.
39. Vespa PM: The implications of cerebral ischemia and meta-
bolic dysfunction for treatment strategies in neurointensive
care.  Curr Opin Crit Care 2006, 12:119-123.
40. Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin
NA, Glenn TC, McArthur DL, Hovda DA: Metabolic crisis without
brain ischemia is common after traumatic brain injury: a com-
bined microdialysis and positron emission tomography study.
J Cereb Blood Flow Metab 2005, 25:763-774.
41. Senda M, Alpert NM, Mackay BC, Buxton RB, Correia JA, Weise
SB, Ackerman RH, Dorer D, Buonanno FS: Evaluation of the 11
CO2 positron emission tomographic method for measuring
brain pH. II. Quantitative pH mapping in patients with ischemic
cerebrovascular diseases.  J Cereb Blood Flow Metab 1989,
9:859-873.
42. Coles JP, Fryer TD, Smielewski P, Rice K, Clark JC, Pickard JD,
Menon DK: Defining ischemic burden after traumatic brain
injury using 15O PET imaging of cerebral physiology.  J Cereb
Blood Flow Metab 2004, 24:191-201.
43. Sakoh M, Ostergaard L, Rohl L, Smith DF, Simonsen CZ,
Sorensen JC, Poulsen PV, Gyldensted C, Sakaki S, Gjedde A:
Relationship between residual cerebral blood flow and oxygen
metabolism as predictive of ischemic tissue viability: sequen-
tial multitracer positron emission tomography scanning of
middle cerebral artery occlusion during the critical first 6
hours after stroke in pigs.  J Neurosurg 2000, 93:647-657.
44. Weiskopf RB, Viele MK, Feiner J, Kelley S, Liberman J, Noorani M,
Leung JM, Fisher DM, Murray WR, Toy P, Moore MA: Human car-
diovascular and metabolic response to acute, severe isovo-
lemic anemia.  JAMA 1998, 279:217-231.
45. Kothaveale A, Banki NM, Kopelnik A, Yarlagadda S, Lawton MT, Ko
N, Smith WS, Drew B, Foster E, Zaroff JG: Predictors of left ven-
tricular regional wall motion abnormalities after subarachnoid
hemorrhage.  Neurocrit Care 2006, 4:199-205.
46. Hare GMT, Tsui AKY, McLaren AT, Ragoonanan TE, Yu J, Mazer
CD: Anemia and cerebral outcomes: Many questions, fewer
answers.  Anesth & Analg 2008, 107:1356-1370.
47. Bruder N, Cohen B, Pellissier D, Francois G: The effect of
hemodilution on cerebral blood flow velocity in anesthetized
patients.  Anesth Analg 1998, 86:320-324.
48. Rebel A, Ulatowski JA, Kwansa H, Bucci E, Koehler RC: Cerebrov-
ascular response to decreased hematocrit: effect of cell-free
hemoglobin, plasma viscosity, and CO2.  Am J Physiol Heart
Circ Physiol 2003, 285:H1600-1608.
49. van Bommel J, Trouwborst A, Schwarte L, Siegemund M, Ince C,
Henny C: Intestinal and cerebral oxygenation during severe
isovolemic hemodilution and subsequent hyperoxic ventila-
tion in a pig model.  Anesthesiology 2002, 97:660-670.
50. Hudetz AG, Wood JD, Kampine JP: 7-Nitroindazole impedes
erythrocyte flow response to isovolemic hemodilution in the
cerebral capillary circulation.  J Cereb Blood Flow Metab 2000,
20:220-224.
51. Hudetz AG, Shen H, Kampine JP: Nitric oxide from neuronal
NOS plays critical role in cerebral capillary flow response to
hypoxia.  Am J Physiol 1998, 274:H982-989.
52. Hare GMT, Mazer CD, Mak W, Gorczynski RM, Hum KM, Kim SY,
Wyard L, Barr A, Qu R, Baker AJ: Hemodilutional anemia isCritical Care    Vol 13 No 3    Kramer and Zygun 
Page 18 of 22
(page number not for citation purposes)
associated with increased cerebral neuronal nitric oxide syn-
thase gene expression.  J Appl Physiol 2003, 94:2058-2067.
53. Plochl W, Liam BL, Cook DJ, Orszulak TA: Cerebral response to
hemodilution during cardiopulmonary bypass in dogs: the role
of nitric oxide synthase.  Br J Anaesth 1999, 82:237-243.
54. Ulatwoski JA, Bucci E, Nishikawa T, Razynska A, Williams MA,
Takeshima R, Traystman RJ, Koehler RC: Cerebral O2 transport
with hematocrit reduced by cross-linked hemoglobin transfu-
sion.  Am J Physiol 1996, 270:H466-475.
55. Todd MM, Farrell S, Wu B: Cerebral blood flow during hypox-
emia and hemodilution in rabbits: different roles for nitric
oxide?  J Cereb Blood Flow Metab 1997, 17:1319-1325.
56. Hare GM, Worrall JM, Baker AJ, Liu E, Sikich N, Mazer CD: Beta2
adrenergic antagonist inhibits cerebral cortical oxygen deliv-
ery after severe hemodilution in rats.  Br J Anaesth 2006,
97:617-623.
57. McLaren AT, Marsden PA, Mazer CD, Baker AJ, Stewart DJ, Tsui
AK, Li X, Yucel Y, Robb M, Boyd SR, Liu E, Yu J, Hare GM:
Increased expression of HIF-1alpha, nNOS, and VEGF in the
cerebral cortex of anemic rats.  Am J Physiol Regul Integr Comp
Physiol 2007, 292:R403-414.
58. Dexter F, Hindman BJ: Effect of haemoglobin concentration on
brain oxygenation in focal stroke: a mathematical modeling
study.  Br J Anaesth 1997, 79:346-351.
59. Todd MM, Wu B, Maktabi M, Hindman BJ, Warner DS: Cerebral
blood flow and oxygen delivery during hypoxemia and anemia:
The role of arterial oxygen content.  Am J Phys 1994,
267:H2025-2031.
60. Korosue K, Heros RC: Mechanism of cerebral blood flow aug-
mentation by hemodilution in rabbits.  Stroke 1992,
23:1487-1492.
61. Cole DJ, Drummond JC, Patel PM, Marcantonio S: Effects of vis-
cosity and oxygen content on cerebral blood flow in ischemic
and normal rat brain.  J Neurol Sci 1994, 124:15-20.
62. Tu YK, Kuo MF, Liu HM: Cerebral oxygen transport and metab-
olism during graded isovolemic hemodilution in experimental
global ischemia.  J Neurol Sci 1997, 150:115-122.
63. Todd MM, Wu B, Warner DS: The hemispheric cerebrovascular
response to hemodilution is attenuated by a focal cryogenic
brain injury.  J Neurotrauma 1994, 11:149-160.
64. Weiskopf RB, Kramer JH, Viele M, Neumann M, Feiner JR, Watson
JJ, Hopf HW, Toy P: Acute severe isovolemic anemia impairs
cognitive function and memory in humans.  Anesthesiology
2000, 92:1646-1652.
65. Weiskopf RB, Toy P, Hopf HW, Feiner J, Finlay HE, Takahashi M,
Bostrom A, Songster C, Aminoff MF: Acute isovolemic anemia
impairs central processing as determined by P300 latency.
Clin Neurophysiol 2005, 116:1028-1032.
66. Ge YL, Lv R, Zhou W, Ma XX, Zhong TD, Duan ML: Brain damage
following severe acute normovolemic hemodilution in combi-
nation with controlled hypotension in rats.  Acta Anaesthesiol
Scand 2007, 51:1331-1337.
67. Lee LA, Deem S, Glenny RW, Townsend I, Moulding J, An D, Treg-
giari MM, Lam A: Effects of anemia and hypotension on porcine
optic nerve blood flow and oxygen delivery.  Anesthesiology
2008, 108:864-872.
68. Czinn EA, Salem MR, Crystal GJ: Hemodilution impairs hypoc-
apnia-induced vasoconstrictor responses in the brain and spi-
nal cord in dogs.  Anesth Analg 1995, 80:492-498.
69. Tu YK, Liu HM: Effects of isovolemic hemodilution on hemody-
namics, cerebral perfusion, and cerebral vascular reactivity.
Stroke 1996, 27:441-445.
70. Kuwabara Y, Sasaki M, Hirakata H, Koga H, Nakagawa M, Chen T,
Kaneko K, Masuda K, Fujishima M: Cerebral blood flow and
vasodilatory capacity in anemia secondary to chronic renal
failure.  Kidney Int 2002, 61:564-569.
71. Tinmouth A, Fergusson D, Yee IC, Hebert PC: ABLE Investiga-
tors; Canadian Critical Care Trials Group. Clinical conse-
quences of red cell storage in the critically ill.  Transfusion
2006, 46:2014-2017.
72. Berezina TL, Zaets SB, Morgan C, Spillert CR, Kamiyama M, Spo-
larics Z, Deitch EA, Machiedo GW: Influence of storage on red
blood cell rheological properties.  J Surg Res 2002, 102:6-12.
73. Tsai AG, Cabrales P, Intaglietta M: Microvascular perfusion
upon exchange transfusion with stored red blood cells in nor-
movolemic anemic conditions.  Transfusion 2004,
44:1626-1634.
74. Heaton A, Keegan T, Holme S: In vivo regeneration of red cell
2,3-diphosphoglycerate following transfusion of DPG-
depleted AS-1, AS-3 and CPDA-1 red cells.  Br J Haematol
1989, 71:131-136.
75. Marik PE, Sibbald WJ: Effect of stored-blood transfusion on
oxygen delivery in patients with sepsis.  JAMA 1993,
269:3024-3029.
76. Walsh TS, McArdle F, McLellan SA, Maciver C, Maginnis M, Pres-
cott RJ, McClelland DB: Does the storage time of transfused
red blood cells influence regional or global indexes of tissue
oxygenation in anemic critically ill patients?  Crit Care Med
2004, 32:364-371.
77. Suttner S, Piper SN, Kumle B, Lang K, Rohm KD, Isgro F, Boldt J:
The influence of allogeneic red blood cell transfusion com-
pared with 100% oxygen ventilation on systemic oxygen trans-
port and skeletal muscle oxygen tension after cardiac surgery.
Anesth Analg 2004, 99:2-11.
78. Gramm J, Smith S, Gamelli RL, Dries DJ: Effect of transfusion on
oxygen transport in critically ill patients.  Shock 1996,
5:190-193.
79. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Bla-
jchman MA: TRALI Consensus Panel.  Transfus Med Rev 2005,
19:2-31.
80. Schorr AF, Duh MS, Kelly KM, Kollef MH: Red blood cell transfu-
sion and ventilator-associated pneumonia: A potential link?
Crit Care Med 2004, 32:666-674.
81. Gunst MA, Minei JP: Transfusion of blood products and noso-
comial infection in surgical patients.  Curr Opin Crit Care 2007,
13:428-432.
82. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Chris-
tiani DC: Clinical predictors of and mortality in acute respira-
tory distress syndrome: potential role of red cell transfusion.
Crit Care Med 2005, 33:1191-1198.
83. Silverboard H, Aisiku I, Martin GS, Adams M, Rozycki G, Moss M:
The role of acute blood transfusion in the development of
acute respiratory distress syndrome in patients with severe
trauma.  J Trauma 2005, 59:717-723.
84. Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A,
Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer
I, vanWalraven C, Devine D, Sher GD: Clinical outcomes follow-
ing institution of the Canadian universal leukoreduction pro-
gram for red blood cell transfusions.  JAMA 2003,
289:1941-1949.
85. Rigamonti A, McLaren AT, Mazer CD, Nix K, Ragoonanan T, Freed-
man J, Harringon A, Hare GM: Storage of strain-specific rat
blood limits cerebral tissue oxygen delivery during acute fluid
resuscitation.  Br J Anaesth 2008, 100:357-364.
86. Weiskopf RB, Kramer JH, Viele M, Neumann M, Feiner JR, Watson
JJ, Hopf HW, Toy P: Acute severe isovolemic anemia impairs
cognitive function and memory in humans.  Anesthesiology
2000, 92:1646-1652.
87. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable
GL:  The International Cooperative Study on the Timing of
Aneurysm Surgery. Part 1: Overall management results.  J
Neurosurg 1990, 73:18-36.
88. Dorsch NW, King MT: A review of cerebral vasospasm in aneu-
rysmal subarachnoid hemorrhage. Part 1: Incidence and
effects.  J Clin Neurosci 1994, 1:19-26.
89. Diringer MN, Yundt K, Videen TO, Adams RE, Zazulia AR, Deibert
E, Aiyagari V, Dacey RG Jr, Grubb RL Jr, Powers WJ: No reduc-
tion in cerebral metabolism as a result of early moderate
hyperventilation following severe traumatic brain injury.  J
Neurosurg 2000, 92:7-13.
90. Menon DK: Brain ischemia after traumatic brain injury: lessons
from 15O2 positron emission tomography.  Curr Opin Crit Care
2006, 12:85-89.
91. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yundt K, Aiyagari
V, Grubb RL Jr, Powers WJ: Hypoperfusion without ischemia
surrounding acute intracerebral hemorrhage.  J Cereb Blood
Flow Metab 2001, 21:804-810.
92. Reeves BC, Murphy GJ: Increased mortality, morbidity, and cost
associated with red blood cell transfusion after cardiac sur-
gery.  Curr Opin Cardiol 2008, 23:607-612.
93. Roach GW, Kanchuger M, Mangano CM, Neuman M, Nussmeier
N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C:
Adverse cerebral outcomes after coronary bypass surgery.
Multicenter Study of Perioperative Ischemia Research GroupAvailable online http://ccforum.com/content/13/3/R89
Page 19 of 22
(page number not for citation purposes)
and the Ischemia Research and Education Foundation Inves-
tigators.  N Engl J Med 1996, 335:1857-1863.
94. McKhann GM, Grega MA, Borowicz LM Jr, Baumgartner WA,
Selnes OA: Stroke and encephalopathy after cardiac surgery:
an update.  Stroke 2006, 37:562-671.
95. Newmann MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H,
Jones RH, Mark DB, Reves JG, Blumenthal JA: Longitudinal
assessment of neurocognitive function after coronary-artery
bypass surgery.  N Engl J Med 2001, 344:395-402.
96. Van Dijk D, Jansen EW, Hijman R, Nierich AP, Diephuis JC, Moons
KG, Lahpor JR, Borst C, Keizer AM, Nathoe HM, Grobbee DE,
DeJaegere PP, Kalkman CJ: Cognitive outcome after off-pump
and on-pump coronary artery bypass graft surgery: a rand-
omized trial.  JAMA 2002, 287:1405-1412.
97. Karkouti K, Wijeysundera DN, Beattie WS, Reducing Bleeding in
Cardiac Surgery (RBC) Investigators: Risk associated with pre-
operative anemia in cardiac surgery: a multicenter cohort
study.  Circulation 2008, 117:478-484.
98. Bell ML, Grunwald GK, Baltz JH, McDonald GO, Bell MR, Grover
FL, Shroyer ALW: Does preoperative hemoglobin independ-
ently predict short-term outcome after coronary artery bypass
graft surgery?  Ann Thorac Surg 2008, 86:1415-1423.
99. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, van Rens-
vurg A, Beattie WS: The influence of baseline hemoglobin con-
centration on tolerance of anemia in cardiac surgery.
Transfusion 2008, 48:666-672.
100. Chang YL, Tsai YF, Lin PJ, Chen MC, Liu CY: Prevalence and risk
factors for post-operative delirium in a cardiovascular inten-
sive care unit.  Am J Crit Care 2008, 17:567-575.
101. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Sny-
der-Ramos SA, Moehnle P, Mangano DT: Impact of preoperative
anemia on outcome in patients undergoing coronary artery
bypass graft surgery.  Circulation 2007, 116:471-479.
102. Matthew JP, Mackensen GB, Phillips-Bute B, Stafford-Smith M,
Podgoreanu MV, Grocott HP, Hill SE, Smith PK, Blumenthal JA,
Reves JG, Newman MF, for the Neruologic Outcome Research
Group (NORG) of the Duke Heart Center: Effects of extreme
hemodilution during cardiac surgery on cognitive function in
the elderly.  Anesthesiology 2007, 107:577-584.
103. Cladellas M, Bruguera J, Cmoin J, Vila J, de Jaime E, Marti J, Gomez
M: Is pre-operative anemia a risk marker for in-hospial mortal-
ity and morbidity after valve replacement?  Eur Heart J 2006,
27:1093-1099.
104. Giltay EJ, Huijskes RV, Kho KH, Blansjaar BA, Rosseel PM: Psy-
chotic symptoms in patients undergoing coronary artery
bypass grafting and heart valve operation.  Eur J Cardiothorac
Surg 2006, 30:140-147.
105. Karkouti K, Djaiani G, Borger MA, Beattie WS, Fedorko L, Wijey-
sundera D, Ivanov J, Karski J: Low hematocrit during cardiopul-
monary bypass is associated with increaed risk of
perioperative stroke in cardiac surgery.  Ann Thorac Surg 2005,
80:1381-1387.
106. Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ,
Shah A: Adverse effects of low hematocrit during cardiopul-
monary bypass in the adult: should current practice be
changed.  J Thorac Cardiovasc Surg 2003, 125:1438-1450.
107. DeFoe GR, Ross CS, Olmstead EM, Surgenor SD, Fillinger MP,
Groom RC, Forest RJ, Pieroni JW, Warren CS, Bogosian ME,
Krumholz CF, Clark C, Clough RA, Weldner PW, Lahey SJ, Leavitt
BJ, Marrin CA, Charlesworth DC, Marshall P, O'Connor GT: Low-
est hematocrit on bypass and adverse outcomes associated
with coronary artery bypass grafting.  Ann Thorac Surg 2001,
71:769-776.
108. van Wermeskerken GK, Lardenoye JW, Hill SE, Grocott HP, Phil-
lips-Bute B, Smith PK, Reves JG, Newman MF: Intraoperative
physiologic variables and outcome in cardiac surgery: Part II.
Neurologic outcome.  Ann Thorac Surg 2000, 69:1077-1083.
109. Klein AA, Nashef SA, Sharples L, Bottrill F, Dyer M, Armstrong J,
Vuylsteke A: A randomized controlled trial of cell salvage in
routine cardiac surgery.  Anesth & Analg 2008, 107:1487-1495.
110. Carless PA, Henry DA, Moxey AJ, O'Connell DL, Brown T, Fergus-
son DA: Cell salvage for minimizing perioperative allogeneic
blood transfusion.  Cochrane Database Syst Rev 2006,
4:CD001888.
111. Society of Thoracic Surgoeons Blood Conservation Guideline
Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan
CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR,
Society of Cardiovascular Anesthesiologists Special Task Force
on Blood Transfusion, Spiess BD, Shore-Lesserson L, Stafford-
Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S: Periop-
erative blood transfusion and blood conservation in cardiac
surgery: the Society of Thoracic Surgeons and The Society of
Cardiovascular Anesthesiologists clinical practice guidelines.
Ann Thorac Surg 2007, 83:S27-86.
112. Taneja R, Fernandes P, Marwaha G, Cheng D, Bainbridge D: Peri-
operative coagulation management and blood conservation in
cardiac surgery: a Canadian Survey.  J Cardiothorac Vasc
Anesth 2008, 22:662-669.
113. Tinmouth AT, McIntyre LA, Fowlder RA: Blood conservation
strategies to reduce the need for red blood cell transfusion in
critically ill patients.  CMAJ 2008, 178:49-57.
114. Jonas RA, Wypij D, Roth SJ, Bellinger DC, Visconti KJ, du Plessis
AJ, Goodkin H, Laussen PC, Farrell DM, Bartlett J, McGrath E,
Rappaport LJ, Bacha EA, Forbess JM, del Nido PJ, Mayer JE Jr,
Newburger JW: The influence of hemodilution on outcome
after hypothermic cardiopulmonary bypass: results of a rand-
omized trial in infants.  J Thorac Cardiovasc Surg 2003,
126:1765-1774.
115. Newburger JW, Jonas RA, Soul J, Kussman BD, Bellinger DC,
Laussen PC, Robertson R, Mayer JE Jr, del Nido PJ, Bacha EA,
Forbess JM, Pigula F, Roth SJ, Visconti KJ, du Plessis AJ, Farrell
DM, McGrath E, Rappaport LA, Wypij D: Randomized trial of
hematocrit 25% versus 35% during hypothermic cardiopulmo-
nary bypass in infant heart surgery.  J Thorac Cardiovasc Surg
2008, 135:347-354.
116. Wypij D, Jonas RA, Bellinger DC, Del Nido PJ, Mayer JE Jr, Bacha
EA, Forbess JM, Pigula F, Laussen PC, Newburger JW: The effect
of hematocrit during hypothermic cardiopulmonary bypass in
infant heart surgery: results from the combined Boston hema-
tocrit trials.  J Thorac Cardiovasc Surg 2008, 135:355-360.
117. Brevig J, McDonald J, Zelinka ES, Gallagher T, Jin R, Grunemeier
GL: Blood transfusion reduction in cardiac surgery: multidisci-
plinary approach at a community hospital.  Ann Thorac Surg
2009, 87:532-539.
118. Ngaage DL, Cowen ME, Griffin S, Guvendik L, Cale AR: Early
neurological complications after coronary artery bypass graft-
ing and valve surgery in octogenarians.  Eur J Cardiothorac
Surg 2008, 33:653-659.
119. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini
GD:  Increased mortality, postoperative morbidity, and cost
after red blood cell transfusion in patients having cardiac sur-
gery.  Circulation 2007, 116:2544-2552.
120. Whitson BA, Huddleston SJ, Savik K, Shumway SJ: Bloodless
cardiac surgery is associated with decreased morbidity and
mortality.  J Card Surg 2007, 22:373-378.
121. Norkiene I, Ringaitiene D, Misiureiene I, Samalavicuius R, Bubulis
R, Baublys A, Uzdavinys G: Incidence and precipitating factors
of delirium after coronary artery bypass grafting.  Scadn Cardi-
ovasc J 2007, 41:180-185.
122. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop "FD,
Starr NJ, Blackstone EH: Morbidity and mortality risk associated
with red blood cell and blood-component transfusion in iso-
lated coronary artery bypass grafting.  Crit Care Med 2006,
34:1608-1616.
123. Stamou SC, White T, Barnett S, Boyce SW, Corso PJ, Lefrak EA:
Comparisons of cardiac surgery outcomes in Jehovah's ver-
sus non-Jehovah's witnesses.  Am J Cardiol 2006,
98:1223-1225.
124. Bucerius J, Gummert JF, Borger MA, Walther T, Doll N, Onnasch
JF, Metz S, Falk V, Mohrt FW: Stroke after cardiac surgery: a risk
factor analysis of 16,184 consecutive adult patients.  Ann Tho-
rac Surg 2003, 75:472-478.
125. D'Ancona G, Saez de Ibarra JI, Baillot R, Mathieu P, Doyle D, Met-
ras J, Desaulniers D, Dagenais F: Determinants of stroke after
coronary artery bypass grafting.  Eur J Cardiothorac Surg 2003,
24:552-556.
126. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T,
Blackstone EH: Duration of red-cell storage and complications
after cardiac surgery.  N Engl J Med 2008, 358:1229-1239.
127. Graham DI, Ford I, Adams JH, Doyle D, Teasdale GM, Lawrence
AE, McLellan DR: Ischemic brain damage is still common in
fatal non-missile head injury.  J Neurol Neurosurg Psychiatry
1989, 52:346-350.Critical Care    Vol 13 No 3    Kramer and Zygun 
Page 20 of 22
(page number not for citation purposes)
128. Bouma GJ, Muizelaar JP, Stringer WA, Choi SC, Fatouros P,
Young HF: Ultra-early evaluation of reiongal cerebral blood
flow in severely head-injured patients using xenon-enhanced
computerized tomography.  J Neurosurg 1992, 77:360-368.
129. Marion DW, Darby J, Yonas H: Acute regional cerebral blood
flow changes caused by severe head injuries.  J Neurosurg
1991, 74:407-414.
130. Gopinath SP, Robertson CS, Contant CF, Hayes C, Feldman Z,
Narayan RK, Grossman RG: Jugular venous desaturation and
outcome after head injury.  J Neurol Neurosurg Psychiatry 1994,
57:717-723.
131. Van Santbrink H, Maas AI, Avezaat CJ: Continuous monitoring of
partial pressure of brain tissue oxygen in patients with severe
head injury.  Neurosurgery 1996, 38:21-31.
132. Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS:
Relationship of brain tissue PO2 to outcome after severe head
injury.  Crit Care Med 1998, 26:1576-1581.
133. Brink WA van den, van Santbrink H, Steyerberg EW, Avezaat CJ,
Suazo JA, Hogesteeger C, Jansen WJ, Koos LM, Vermeulen J,
Maas AI: Brain oxygen tension in severe head injury.  Neurosur-
gery 2000, 46:868-876.
134. Diringer MN, Videen TO, Yundt K, Zazulia AR, Aiyagari V, Dacey
RG Jr, Grubb RL, Powers WJ: Regional cerebrovascular and
metabolic effects of hyperventilation after severe traumatic
brain injury.  J Neurosurg 2002, 96:103-108.
135. Coles JP: Regional ischemia after head injury.  Curr Opin Crit
Care 2004, 10:120-125.
136. Abate MG, Trivedi M, Fryer TD, Smielewski P, Chatfield DA, Wil-
liams GB, Aigbirhio F, Carpenter TA, Pickard JD, Menon DK, Coles
JP: Early derangements in oxygen and glucose metabolism
following head injury: the ischemic penumbra and pathophys-
iological heterogeneity.  Neurocrit Care 2008, 9:319-325.
137. Nortje J, Coles JP, Timofeev I, Fryer TD, Aigbirhio FI, Smielewsi P,
Outtrim JG, Chatfield DA, Pichard JD, Hutchinson PJ, Gupta AK,
Menon DK: Effect of hyperoxia on regional oxygenation and
metabolism after severe traumatic brain injury: preliminary
findings.  Crit Care Med 2008, 36:273-281.
138. Hare GM, Mazer CD, Hutchison JS, McLaren AT, Liu E, Rassouli
A, Ai J, Shaye RE, Lockwood JA, Hawkins CE, Sikich N, To K,
Baker AJ: Severe hemodilutional anemia increases cerebral
tissue injury following acute neurotrauma.  J Appl Physiol
2007, 103:1021-1029.
139. Smith MJ, Stiefel MF, Magge S, Frangos S, Bloom S, Gracias V, Le
Roux PD: Packed red blood cell transfusion increases local
cerebral oxygenation.  Crit Care Med 2005, 33:1104-1108.
140. Leal-Noval SR, Rincon-Ferrari MD, Marin-Niebla A, Cayuela A,
Arellano-Orden V, Marin-Caballos A, Amaya-Villar R, Ferrandiz-Mil-
lon C, Murillo-Cabeza F: Transfusion of erythrocyte concen-
trates produces a variable increment on cerebral oxygenation
in patients with severe traumatic brain injury: a preliminary
study.  Intensive Care Med 2006, 32:1733-1740.
141. Leal-Noval SR, Munoz-Gomez M, Aerllano-Orden V, Marin-Cabal-
los A, Amaya-Villar R, Marin A, Puppo-Moreno A, Ferrandiz-Millon
C, Flores-Cordero JM, Murillo-Cabezas F: Impact of age of trans-
fused blood on cerebral oxygenation in male patients with
severe traumatic brain injury.  Crit Care Med 2008,
36:1290-1296.
142. Zygun D, Nortje J, Hutchinson PJ, Timofeev I, Menon DK, Gupta
AK: Effect of red blood cell transfusion on cerebral oxygena-
tion and metaoblism following severe trauamtic brain injury.
Crit Care Med 2009, 37:1074-1078.
143. Carlson AP, Schermer CR, Lu SW: Retrospective evaluation of
anemia and transfusion in traumatic brain injury.  J Trauma
2006, 61:46-56.
144. Steyerberg EW, Mushkuidani N, Perel P, Butcher I, Lu J, McHugh
GS, Murray GD, Marmarou A, Robets I, Habbema JDF, Maas AIR:
Predicting outcome after traumatic brain injury: development
and validation of international validation of prognostic scores
based on admission characteristics.  PLoS Med 2008,
5:1251-1261.
145. Duane TM, Mayglothling J, Grandhi R, Warrier N, Aboutanos MB,
Wolfe LG, Malhotra AK, Ivatury RR: The effect of anemia and
blood transfusions on mortality in closed head injury patients.
J Surg Res 2008, 147:163-167.
146. Salim A, Hadjizacharia P, DuBose J, Brown C, Inaba K, Chan L,
Margulies DR: Role of anemia in traumatic brain injury.  J Am
Coll Surg 2008, 207:398-406.
147. George ME, Skarda DE, Watts CR, Pham HD, Beilman GJ:
Aggressive red blood cell transfusion: no association with
improved outcomes for victims of isolated traumatic brain
injury.  NeuroCrit Care 2008, 8:337-343.
148. Van Beek JGM, Mushkudiani NA, Steyerberg EW, Butcher I,
McHugh GS, Lu J, Marmarou A, Murrary GD, Maas AIR: Prognos-
tic value of admission laboratory parameters in traumatic
brain injury: results from the IMPACT Study.  J Neurotrauma
2007, 24:315-328.
149. Schirmer-Makalsen K, Vik A, Gisvold SE, Skandsen T, Hynne H,
Klepstad P: Severe head injury: control of physiological varia-
bles, organ failure and complications in the intensive care unit.
Acta Anaesthesiol Scand 2007, 51:1194-1201.
150. McIntyre LA, Fergusson DA, Hutchison JS, Pagliarello G, Marshall
JC, Yetisir E, Hare GM, Hébert PC: Effect of a liberal versus
restrictive transfusion strategy on mortality in patients with
moderate to severe head injury.  NeuroCrit Care 2006, 5:4-9.
151. Robertson CS, Gopinath SP, Goodman JC, Contant CF, Valadka
AB, Narayan RK: SjvO2 monitoring in head-injured patients.  J
Neurotrauma 1995, 12:891-896.
152. Bendel P, Koivisto T, Kononen M, Hanninen T, Huarskainen H,
Saari T, Vapalahti M, Hernesniemi J, Vanninen R: MR imaging of
the brain 1 year after aneurysmal subarachnoid hemorrhage:
randomized study comparing surgical with endovascular
treatment.  Radiology 2008, 246:543-552.
153. Shimoda M, Takeuchi M, Tominaga J, Oda S, Kumasaka A, Tsug-
ane R: Asymptomatic versus symptomatic infarcts from vasos-
pasm in patients with subarachnoid hemorrhage: serial
magnetic resonance imaging.  Neurosurgery 2001,
49:1341-1348.
154. Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan
B: Relationship between hemoglobin concentrations and out-
comes across subgroups of patients with aneurysmal sub-
arachnoid hemorrhage.  NeuroCrit Care 2009, 10:20-27.
155. Naidech AM, Drescher J, Ault ML, Shaibani A, Batjer HH, Alberts
MJ: Higher hemoglobin is associated with less cerebral infarc-
tion, poor outcome, and death after subarachnoid hemor-
rhage.  Neurosurgery 2006, 59:775-779.
156. Naidech AM, Jovanovic B, Wartenberg KE, Parra A, Ostapkovich
N, Connolly ES, Mayer SA, Commichau C: Higher hemoglobin is
associated with improved outcome after subarachnoid hem-
orrhage.  Crit Care Med 2007, 35:2383-2389.
157. Tseng MY, Hutchinson PJ, Kirkpatrick PJ: Effects of fluid therapy
following aneurismal subarachnoid hemorrhage: a prospec-
tive clinical study.  Br J Neurosurg 2008, 22:257-268.
158. Wartenberg KE, Schmidt JM, Claassen J, Temes RE, Frontera JA,
Ostapkovich N, Parra A, Connolly ES, Mayer SA: Impact of med-
ical complications on outcome after subarachnoid hemor-
rhage.  Crit Care Med 2006, 34:617-623.
159. DeGeorgia M, Deogaonkar A, Ondrejka J, Katzan I, Sabharwal V,
Woo HH, Rasmussen P, Chow M, Mayberg M: Blood transfu-
sionfollowing subarachnoid hemorrhage worsens outcome.
[http://www.abstractonline.com/arch/RecordView.aspx?Lookup
Key=12345&recordID=11885].
160. Smith MJ, Le Roux PD, Elliott JP, Winn HR: Blood transfusion
and increased risk for vasospasm and poor outcome after
subarachnoid hemorrhage.  J Neurosurg 2004, 101:1-7.
161. Sen J, Belli A, Albon H, Morgan L, Petzold A, Kitchen N: Triple-H
therapy in the management of aneurysmal subarachnoid hem-
orrhage.  Lancet Neurol 2003, 2:614-621.
162. Ekelund A, Reinstrup P, Ryding E, Andersson AM, Molund T, Kris-
tiansson KA, Romner B, Brandt L, Saveland H: Effects of iso- and
hypervolemic hemodilution on regional cerebral blood flow
and oxygen delivery for patients with vasospasm after aneu-
rysmal subarachnoid hemorrhage.  Acta Neurochir 2002,
144:703-712.
163.Muench E, Horn P, Bauhuf C, Roth H, Philipps M, Hermann P,
Quintel M, Schmiedek P, Vajkoczy P: Effects of hypervolemia
and hypertension on regional cerebral blood flow, intracranial
pressure, and brain tissue oxygenation after subarachnoid
hemorrhage.  Crit Care Med 2007, 35:1844-1851.
164. Dhar R, Zazulia A, Videen T, Diringer M: Red blood cell transfu-
sion increases cerebral oxygen delivery after subarachnoid
hemorrhage.  NeuroCrit Care 2008, 9:S5.
165. Oddo M, Milby A, Chen I, Frangos S, Maloney-Wilensky E, Stiefel
M, Kofke WA, Levine JM, Le Roux PD: Hemoglobin level and cer-
ebral metabolism in patients with aneurysmal subarachnoidAvailable online http://ccforum.com/content/13/3/R89
Page 21 of 22
(page number not for citation purposes)
hemorrhage: a microdialysis study.  Stroke 2009,
40:1275-1281.
166. Grotta J, Ackerman R, Correia J, Fallick G, Chang J: Whole blood
viscosity parameters and cerebral blood flow.  Stroke 1982,
13:296-301.
167. Tohgi H, Yamanouchi H, Murakami M, Kameyama M: Importance
of the hematocrit as a risk factor in cerebral infarction.  Stroke
1978, 9:369-374.
168. Roh JK, Kang DW, Lee SH, Yoon BW, Chang KH: Significance of
acute multiple brain infarction on diffusion-weighted imaging.
Stroke 2000, 31:688-694.
169. Arauz A, Murillo L, Cantu C, Barinagarrementeria F, Higuera J: Pro-
spective study of single and multiple lacunar infarcts using
magnetic resonance imaging: risk factors, recurrence, and
outcome in 175 consecutive cases.  Stroke 2003,
34:2453-2458.
170. Longo-Mbenza B, Lelo Tshinkwela M, Mbuilu Pukuta J: Rates and
predictors of stroke-associated case fatality in black Central
African patients.  Cardiovasc J Afr 2008, 19:72-76.
171. Kannel WB, Gordon T, Wolf PA, McNamara P: Hemoglobin and
the risk of cerebral infarction: the Framingham study.  Stroke
1972, 3:409-420.
172. Gagnon DR, Zhang TJ, Brand FN, Kannel WB: Hematocrit and
the risk of cardiovascular disease – the Framingham study: a
34 year follow-up.  Am Heart J 1994, 127:674-682.
173. Wannamethee G, Perry IJ, Shaper AG: Hematocrit, hypertension
and risk of stroke.  J Intern Med 1994, 235:163-168.
174. Sacco S, Marini C, Olivieri L, Pistoia F, Carolei A: Contribution of
hematocrit to early mortality after ischemic stroke.  Eur Neurol
2007, 58:233-238.
175. Diamond PT, Gale SD, Evans BA: Relationship of initial hemat-
ocrit level to discharge destination and resource utilization
after ischemic stroke: a pilot study.  Arch Phys Med Rehabil
2003, 84:964-967.
176. Harrison MJ, Pollock S, Kendall BE, Marshall J: Effect of hemat-
ocrit on carotid stenosis and cerebral infarction.  Lancet 1981,
2:114-115.
177. Lowe GDO, Jaap AJ, Forbes CD: Relation of atrial fibrillation
and high hematocrit to mortality in acute stroke.  Lancet 1983,
1:784-786.
178. Allport LE, Parsons MW, Butcher KS, MacGregor L, Desmond PM,
Tress BM, Davis SM: Elevated hematocrit is associated with
reduced reperfusion and tissue survival in acute stroke.  Neu-
rology 2005, 65:1382-1387.
179. Huang WY, Chen IC, Meng L, Weng WC, Peng TI: The influence
of anemia on clinical presentation and outcome of patients
with first-ever atherosclerosis-related ischemic stroke.  J Clin
Neurosci 2009, 16:645-649.
180. Huang WY, Weng WC, Chien YY, Wu CL, Peng TI, Chen KH:
Predictive factors of outcome and stroke recurrence in
patients with unilateral atherosclerosis-related internal carotid
artery occlusion.  Neurol India 2008, 56:173-178.
181. Nybo M, Kristensen SR, Mickley H, Jensen JK: The influence of
anemia on stroke prognosis and its relation to N-terminal pro-
brain natriuretic peptide.  Eur J Neurol 2007, 14:477-482.
182. Bhatia RS, Garg RK, Gaur SPS, Kar AM, Shukla R, Agarwal A,
Verma R: Predictive value of routine hematological and bio-
chemical parameters on 30-day fatality in acute stroke.  Neurol
India 2004, 52:220-223.
183. Wade JP, Taylor DW, Barnett HJ, Hachinksi VC: Hemoglobin
concentration and prognosis in symptomatic obstructive cere-
brovascular disease.  Stroke 1987, 18:68-71.
184. LaRue L, Alter M, Lai SM, Friday G, Sobel E, Levitt L, McCoy R,
Isack T: Acute stroke, hematocrit, and blood pressure.  Stroke
1987, 18:565-569.
185.Kusonoki M, Kimura K, Nakamura M, Isaka Y, Yoneda S, Abe H:
Effects of hematocrit variations on cerebral blood flow and
oxygen transport in ischemic cerebrovascular disease.  J
Cereb Blood Flow Metab 1981, 1:413-417.
186. Xiong L, Lei C, Wang Q, Li W: Acute normovolemic hemodilu-
tion with a novel hydroxyethylstarch (130/0.4) reduces focal
cerebral ischemic injury in rats.  Eur J Anaesthesiol 2008,
25:581-588.
187. Lee SH, Heros RC, Mullan JC, Korosue K: Optimum degree of
hemodilution for brain protection in a canine model of focal
cerebral ischemia.  J Neurosurg 1994, 80:469-475.
188. Reasoner DK, Ryu KH, Hindman BJ, Cutkomb J, Smith T: Marked
hemodilution increases neurologic injury after focal cerebral
ischemia in rabbits.  Anesth Analg 1996, 82:61-67.
189. Kim JS, Kang SY: Bleeding and subsequent anemia: a precipi-
tant for cerebral infarction.  Eur Neurol 2000, 43:201-208.
190. Bosel J, Ruscher K, Ploner CJ, Valdueza JM: Delayed neurologi-
cal deterioration in a stroke patients with postoperative acute
anemia.  Eur Neurol 2005, 53:36-38.
191. Shahar A, Sadeh M: Severe anemia associated with transient
neurological deficits.  Stroke 1991, 22:1201-1202.
192. Asplund K: Hemodilution for acute ischemic stroke.  Cochrane
Database Syst Rev 2002, 2:CD000103.
193. Italian Acute Stroke Study Group: Hemodilution in acute stroke:
results from the Italian Hemodilution Trial.  Lancet 1998,
13:318-321.
194. Scandinavian Stroke Study Group: Multicenter trial of hemodilu-
tion in acute ischemic stroke: I. Results in the toal patient pop-
ulation.  Stroke 1987, 18:691-699.
195. Goslinga H, Eijzenbach V, Heuvelmans JH, Laan de Vries E van
der, Melis VM, Schmid-Schoenbein H, Bezemer PD: Custom-tai-
lored hemodilution with albumin and crystalloids in acute
ischemic stroke.  Stroke 1992, 23:181-188.
196. Aichner FT, Fazekas F, Brainin M, Polz W, Mamoli B, Zeiler K: Hyp-
ervolemic hemodilution in acute ischemic stroke: the Multi-
center Austrian Hemodilution Stroke Trial (MAHST).  Stroke
1998, 29:743-749.
197. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD: Effect of
delayed albumin hemodilution on infarction volume and brain
edema after transient middle cerebral artery occlusion in rats.
J Neurosurg 1997, 87:595-601.
198. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD: The
ALIAS Pilot Trial: a dose-escalation and safety study of albu-
min therapy for acute ischemic stroke – II: neurologic outcome
and efficacy analysis.  Stroke 2006, 37:2107-2114.
199. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D: The
ALIAS Pilot Trial: a dose-escalation and safety study of albu-
min therapy for acute ischemic stroke – I: physiological
responses and safety results.  Stroke 2006, 37:2100-2106.
200. Shin DH, Moon GJ, Bang OY: Albumin therapy in acute stroke
patients.  J Neurol 2007, 254:870-878.
201. Mayer SA, Rincon F: Management of intracerebral hemorrhage.
Lancet Neurol 2005, 4:662-672.
202. Mendelow AD: Mechanisms of ischemic damage with intracer-
ebral hemorrhage.  Stroke 1993, 24:115-119.
203. Siddique MS, Fernandes HM, Wooldridge TD, Fenwick JD,
Slomka P, Mendelow AD: Reversible ischemia around intracer-
ebral hemorrhage: a single-photon emission computerized
tomography study.  J Neurosurg 2002, 96:736-741.
204. Schellinger PD, Fiebach JB, Hoffmann K, Becker K, Orakcioglu B,
Kollmar R, Juttler E, Schramm P, Schwab S, Sartor K, Hacke W:
Stroke MRI in intracerebral hemorrhage: is there a perihemor-
rhagic penumbra?  Stroke 2003, 34:1674-1679.
205. Rosand J, Eskey C, Chang Y, Gonzalez RG, Greenberg SM, Koro-
shetz WJ: Dynamic single-section CT demonstrates reduced
cerebral blood flow in acute intracerebral hemorrhage.  Cere-
brovasc Dis 2002, 14:214-220.
206. Herweh C, Juttler E, Schellinger PD, Klotz E, Jenetzky E, Orakci-
oglu B, Sartor K, Schramm P: Evidence against a perihemor-
rhagic penumbra provided by perfusion computed
tomography.  Stroke 2007, 38:2941-2947.
207. Nilsson OG, Polito A, Saveland H, Ungerstedt U, Norstrom CH:
Are the primary supratentorial intracerebral hemorrhages sur-
rounded by a biochemical penumbra? A microdialysis study.
Neurosurgery 2006, 59:521-528.
208.Aronowski J, Strong R, Grotta JC: Combined neuroprotection
and reperfusion therapy for stroke. Effect of lubeluzole and
diaspirin cross-linked hemoglobin in experimental focal
ischemia.  Stroke 1996, 27:1571-1576.
209. Bowes MP, Burhop KE, Zivin JA: Diaspirin cross-linked hemo-
globin improves neurological outcome following reversible
but not irreversible CNS ischemia in rabbits.  Stroke 1994,
25:2253-2257.
210. Cole DJ, Drummon JC, Patel PM, Reynolds LR: Hypervolemic-
hemodilution during cerebral ischemia in rat: effects of diaspi-
rin cross-linked hemoglobin (DCLHb) on neurological out-
come and infarct volume.  J Neurosurg Anesthesiol 1997,
9:44-50.Critical Care    Vol 13 No 3    Kramer and Zygun 
Page 22 of 22
(page number not for citation purposes)
211. Mito T, Nemoto M, Kwansa H, Samepi K, Habeeb M, Murphy SJ,
Bucci E, Koehler RC: Decreased damage from transient focal
cerebral ischemia by transfusion of zero-link hemoglobin pol-
ymers in mouse.  Stroke 2009, 40:278-284.
212. Nemoto M, Mito T, Brinigar WS, Fronticelli C, Koehler RC: Sal-
vage of focal cerebral ischemic damage by transfusion of high
O2-affinity recombinant hemoglobin polymers in mouse.  J
Appl Physiol 2006, 100:1688-1691.
213. Piper IR, Garrioch MA, Souter MJ, Andrews PJ, Thomson D:
Effects of diaspirin cross-linked hemoglobin on post-trau-
matic cerebral persuion pressure and blood flow in a rodent
model of diffuse brain injury.  Br J Anaesth 1998, 80:639-643.
214. Gibson JB, Maxwell RA, Schwiezter JB, Fabian TC, Proctor KG:
Resuscitation from severe hemorrhagic shock after tramatic
brain injury using saline, shed blood, or a blood substitute.
Shock 2002, 17:234-244.
215. Chappell JE, Shackford SR, McBride WJ: Effect of hemodilution
with diaspirin cross-linked hemoglobin on intracranial pres-
sure, cerebral perfusion pressure, and fluid reuirements after
head injury and shock.  J Neurosurg 1997, 86:131-138.
216. Dudkiewicz M, Harpaul TA, Proctor KG: Hemoglobin-based oxy-
gen carrying compound-201 as salvage therapy for severe
neuro-and polytrauma (Injury Severity Score = 27–41).  Crit
Care Med 2008, 36:2838-2848.
217. Stern S, Rice J, Philbin N, McGwin G, Arnaud F, Johnson T,
Flournoy WS, Ahlers S, Pearce LB, McCarron R, Freilich D:
Resuscitation with the hemoglobin-based oxygen carrier,
HOBC-201, in a swine model of severe uncontrolled hemor-
rhage and traumatic brain injury.  Shock 2009, 31:64-79.
218. Rosenthal G, Morabito D, Cohen M, Roeytenberg A, Derugin N,
Panter SS, Knodson MM, Maley G: Use of hemoglobin-based
oxygen-carrying solution-201 to improve resuscitation param-
eters and prevent secondary brain injury in a swine model of
traumatic brain injury and hemorrhage; laboratory investiga-
tion.  J Neurosurg 2008, 108:575-587.
219. Kerby JD, Sainz JG, Zhang F, Hutchings A, Sprague S, Farrokhi FR,
Son M: Resuscitation from hemorrhagic shock with HOBC-201
in the setting of traumatic brain injury.  Shock 2007,
27:652-656.
220. Cole DJ, Reynolds LW, Nary JC, Drummond JC, Patel PM, Jacob-
sern WK: Subarachnoid hemorrhage in rats: effect of singular
or sustained hemodilution with alpha-alpha diaspirin
crosslinked hemoglobin on cerebral hypoperfusion.  Crit Care
Med 1999, 27:972-977.
221. Cole DJ, Nary JC, Reynolds LW, Patel PM, Drummond JC: Exper-
imental subarachnoid hemorrhage in rats: effect of intrave-
nous alpha-alpha diaspitin crosslinked hemoglobin on
hypoperfusion and neuronal death.  Anesthesiology 1997,
87:1486-1493.
222. Rother RP, Bell L, Hillmen P, Gladwin MT: The clinical sequelae
of intravascular hemolysis and extracellular plasma hemo-
globin: a novel mechanism of human disease.  JAMA 2005,
293:1653-1662.
223. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM: Cell-free
hemoglobin-based blood substitutes and risk of myocardial
infarction and death.  JAMA 2008, 299:2304-2312.
224. Saxena R, Wihnhoud AD, Carton H, Hacke W, Kaste M, Przybelski
RJ, Stern KN, Koudstaal PJ: Controlled safety study of a hemo-
globin-based oxygen carrier, DCLHb, in acute ischemic stroke.
Stroke 1999, 30:993-996.
225. Kerner T, Ahlers O, Veit S, Riou B, Saunders M, Pison U, for the
European DCLHb Trauma Study Group: DCL-Hb for trauma
patients with severe hemorrhagic shock: the European "On-
Scene" Multicenter Study.  Intensive Care Med 2003,
29:378-385.
226. Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory
MN, Rodman G, for the DCLHb Traumatic Hemorrhagic Shock
Study Group: Diaspirin cross-linked hemoglobin (DCLHb) in
the treatment of severe traumatic hemorrhagic shock: a rand-
omized controlled efficacy trial.  JAMA 1999, 282:1857-1864.
227. Gould SA, Moore EE, Hoyt DB, Burch JM, Haenel JB, Garcia J,
DeWoskin R, Moss GS: The first randomized trial of human
polymerized hemoglobin as a blood substitute in acute
trauma and emergent surgery.  J Am Coll Surg 1998,
187:113-120.
228. Przybelski RJ, Daily EK, Micheels J, Sloan E, Mols P, Corne L,
Koenigerg MD, Bickell WH, Thompson DR, Harviel JD, Cohn SM:
A safety assessment of diaspirin cross-linked hemoglobin
(DCLHb) in the treatment of hemorrhagic, hypovolemic shock.
Prehosp Disaster Med 1999, 14:251-264.
229. Moore EE, Moore FA, Fabian TC, Bernard AC, Fulda GJ, Hoyt DB,
Duane TM, Weireter LJ, Gomez GA, Ciplle MD, Rodman GH,
Malangoni MA, Hides GA, Omert LA, Gould SA: Human polym-
erized hemoglobin for the treatment of hemorrhagic shock
when blood is unavailable: the USA multicenter trial.  J Am Coll
Surg 2009, 208:1-13.
230. Lamy ML, Daily EK, Brichant JF, Larbuisson RP, Demeyere RH,
Vandermeersch EA, Lehot JJ, Parsloe MR, Berridge JC, Sinclair CJ,
Baron JF, Przybelski RJ, for the DCLHb Cardiac Surgery Trial Col-
laborative Group: Randomized trial of diaspirin cross-linked
hemoglobin solution as an alternative to blood transfusion
after cardiac surgery.  Anesthesiology 2000, 92:646-656.
231. Hill SE, Gottshcalk LI, Grichnik K: Safety and preliminary effi-
cacy of hemoglobin raffimer for patients undergoing coronary
artery bypass surgery.  J Cardiothorac Vasc Anesth 2002,
16:695-702.
232. Lindsay P, Bayley M, Hellings C, Hill M, Woddbury E, Phillips S:
Canadian best practice recommendations for stroke care
(updated 2008).  CMAJ 2008, 179:S1-25.
233. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan
A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Mor-
genstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF,
American Heart Association; American Stroke Association Stroke
Council; Clinical Cardiology Council; Cardiovascular Radiology
and Intervention Council; Atherosclerotic Peripheral Vascular Dis-
ease and Quality of Care Outcomes in Research Interdisciplinary
Working Groups: Guidelines for the early management of
adults with ischemic stroke: a guideline from the American
Heart Association/American Stroke Association Stroke Coun-
cil, Clinical Cardiology Council, Cardiovascular Radiology and
Intervention Council, and the Atherosclerotic Peripheral Vas-
cular Disease and Quality of Care Outcomes in Research
Interdisciplinary Working Groups: the American Academy of
Neurology affirms the value of this guideline as an educational
tool for neurologists.  Stroke 2007, 38:1655-1711.
234. Brain Trauma Foundation; American Association of Neurological
Surgeons; Congress of Neurological Surgeons: Guidelines for
the management of severe traumatic brain injury.  J Neuro-
trauma 2007, 24:S1-106.
235. Bederson JB, Connolly ES, Batjer HH, Dacey RG, Dion JE, Dir-
inger MN, Duldner JE, Harbaugh RE, Patel AB, Rosenwasser RH:
Guidelines for the management of aneurysmal subarachnoid
hemorrhage.  Stroke 2009, 40:994-1025.
236. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D,
Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M,
American Stroke Association Stroke Council; High Blood Pres-
sure Research Council; Quality of Care and Outcomes in
Research Interdisciplinary Working Group: Guidelines for the
management of spontaneous intracerebral hemorrhage in
adults: 2007 update: a guideline from the American Heart
Association/American Stroke Association Stroke Council,
High Blood pressure Research Council, and the Quality of
Care and Outcomes in Research Interdisciplinary Working
Group.  Stroke 2007, 38:2001-2023.
237. Chang JJ, Youn TS, Benson D, Mattick H, Andrade BA, Harper MS,
Moore CB, Madden CJ, Diaz-Arrastia RR: Physiologic and func-
tional outcome correlates of brain tissue hypoxia in traumatic
brain injury.  Crit Care Med 2009, 37:283-290.
238. Naidech AM, Bendok BR, Ault ML, Bleck TP: Monitoring with the
Somanetics INVOS 5100C after aneurysmal subarachnoid
hemorrhage.  Neurocrit Care 2008, 9:326-331.
239. Sahuquillo J, Poca MA, Garnacho A, Robles A, Coello F, Godet C,
Triginer C, Rubio E: Early ischemia after severe head injury.
Preliminary results in patients with diffuse brain injuries.  Acta
Neurochir 1993, 122:204-214.
240. Cruz J, Jaggi JL, Hoffstad OJ: Cerebral blood flow and oxygen
consumption in acute brain injury with acute anemia: an alter-
native for the cerebral metabolic rate of oxygen consumption?
Crit Care Med 1993, 21:1218-1224.